Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.
- Authors
- Cibulskis, Kristian; Lawrence, Michael S; Carter, Scott L; Sivachenko, Andrey; Jaffe, David; Sougnez, Carrie; Gabriel, Stacey; Meyerson, Matthew; Lander, Eric S; Getz, Gad
- Year
- 2013
- Journal
- Nature biotechnology
- PMID
- 23396013
- DOI
- 10.1038/nbt.2514
- PMCID
- PMC3833702
Detection of somatic point substitutions is a key step in characterizing the cancer genome. However, existing methods typically miss low-allelic-fraction mutations that occur in only a subset of the sequenced cells owing to either tumor heterogeneity or contamination by normal cells. Here we present MuTect, a method that applies a Bayesian classifier to detect somatic mutations with very low allele fractions, requiring only a few supporting reads, followed by carefully tuned filters that ensure high specificity. We also describe benchmarking approaches that use real, rather than simulated, sequencing data to evaluate the sensitivity and specificity as a function of sequencing depth, base quality and allelic fraction. Compared with other methods, MuTect has higher sensitivity with similar specificity, especially for mutations with allelic fractions as low as 0.1 and below, making MuTect particularly useful for studying cancer subclones and their evolution in standard exome and genome sequencing data.
Overview of somatic point mutation detection using MuTect.MuTect takes as input tumor (T) and normal (N) next generation sequencing data and, after removing low quality reads (Supplementary Methods), determines if there is evidence for a variant beyond the expected random sequencing errors. Candidate variant sites are then passed through six filters to remove artifacts (Table 1). Next, a Panel of Normals is used to screen out remaining false positives caused by rare error modes only detectable in additional samples. Finally, the somatic or germline status of passing variants is determined using the matched normal.
Sensitivity as a function of sequencing depth and allelic fraction.(a) Sensitivity and specificity of MuTect for mutations with an allele fraction of 0.2, tumor depth of 30x and normal depth of 30x using various values of the LOD threshold (ΞΈT) (0.1 β€ ΞΈT β€ 100). Results using a model of independent sequencing errors with uniform Q35 base quality scores and accurate read placement (solid grey) are shown as well as results from the virtual tumor approach for the standard (STD, dashed green) and high-confidence (HC, solid green) configurations. A typical setting of ΞΈT = 6.3 is marked with black circles. (b) Sensitivity as a function of tumor sequencing depth and allele fraction (indicated by color) using ΞΈT = 6.3. The calculated sensitivity using a model of independent sequencing errors and accurate read placement with uniform Q35 base quality scores (solid lines) are shown as well as results from the virtual tumor approach (circles) and the downsampling of validated colorectal mutations7 (diamonds). Error bars represent 95% CIs.
Specificity of variant detection and variant classification using virtual tumor approach. (a) Somatic miscall error rate for true reference sites as a function of tumor sequencing depth for the STD (red), HC (blue) and HC+PON (green) configurations of MuTect. Error bars represent 95% CIs. (b) Distribution of allele fraction for all miscalls as a function of tumor sequencing depth. (c) Fraction of events rejected by each filter; hashed regions indicate events rejected exclusively by each filter. (d) Somatic miscall error rate for true germline SNP sites by sequencing depth in the normal when the site is known to be variant in the population (blue) and novel (red). Error bars represent 95% CIs. (e,f) Mean power as a function of sequencing depth in the normal to have classified these events as germline or somatic at novel germline sites (e) and known germline variant sites (f).
Benchmarking mutation detection methods. (a) Comparison of sensitivity as a function of tumor sequencing depth and mutation allele fraction for different mutation detection methods and configurations. (b) Comparison of somatic miscall error rate for true germline sites as a function of sequencing depth in the normal. (c) Comparison of somatic miscall error rate for true reference sites as a function of tumor sequencing depth. (d) Sensitivity as a function of specificity for mutations with an allele fraction of 0.1, tumor depth of 30x and normal depth of 30x between different methods and configurations. Black dotted lines indicate change in sensitivity and specificity between STD and HC configurations for a method. Grey solid lines are the MuTect results of virtual tumor approach from Supplementary Figure 3. (aβc) Error bars represent 95% CIs.
| Name | Type |
|---|---|
| 1000 Genomes Project | cohort |
| 30x coverage local | phenotype |
| 60x coverage local | phenotype |
| Allele fraction 0.05 local | phenotype |
| Allele fraction 0.1 local | phenotype |
| Allele fraction 0.4 local | phenotype |
| cancer | phenotype |
| chronic lymphocytic leukemia | phenotype |
| Clonal mutations local | variant |
| coding regions local | phenotype |
| COLO-829 melanoma cell line local | cohort |
| colorectal cancer | phenotype |
| complex subclonal structure local | phenotype |
| Contaminating DNA local | drug |
| COSMIC local | drug |
| dbGaP | cohort |
| Down-sampling local | drug |
| exome local | drug |
| False Positive Mutation Call local | phenotype |
| false positive rate | phenotype |
| filters local | drug |
| germline local | phenotype |
| Germline events local | variant |
| Germline heterozygous event local | variant |
| germline heterozygous variant local | variant |
| germline mutation local | phenotype |
| Germline SNP local | variant |
| germline variant loci local | variant |
| HC configuration local | cohort |
| HC configuration local | drug |
| Illumina HiSeq | drug |
| International Cancer Genome Consortium local | cohort |
| JointSNVMix local | drug |
| known mutations local | variant |
| LOD score local | drug |
| low-allele fraction events local | phenotype |
| low purity samples local | phenotype |
| m local | variant |
| matched normal local | cohort |
| Metastases local | phenotype |
| Mfm local | cohort |
| mutations | variant |
| MuTect local | drug |
| NA12878 | cohort |
| NA12891 local | cohort |
| NA12981 local | cohort |
| normal | phenotype |
| normal sample local | cohort |
| normal samples | cohort |
| panel of normal local | cohort |
| panel of normal samples local | cohort |
| Panel of Normals filter local | drug |
| phs000178 local | cohort |
| public germline variation databases local | drug |
| reference allele | variant |
| Sample A local | cohort |
| Sample B local | cohort |
| sensitivity local | phenotype |
| Solexa-18483 local | cohort |
| Solexa-18484 local | cohort |
| Solexa-23661 local | cohort |
| solid tumor cancer patients local | cohort |
| somatic | phenotype |
| somatic mutation local | phenotype |
| Somatic single-nucleotide substitution local | variant |
| SomaticSniper local | drug |
| SomaticSpike local | drug |
| specificity local | phenotype |
| Standard configuration local | cohort |
| Strelka local | drug |
| Subclonality local | phenotype |
| subclonal mutations | variant |
| The Cancer Genome Atlas | cohort |
| time to therapy local | phenotype |
| tumor local | cohort |
| tumor | phenotype |
| Tumor DNA local | drug |
| Tumors local | phenotype |
| Tumor type local | phenotype |
| tumor types local | phenotype |
| validated somatic mutations local | variant |
| variant | cohort |
| variant allele m local | variant |
| Virtual tumor local | cohort |
| Virtual tumor approach local | drug |
| virtual tumors benchmark local | cohort |
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial. | Brastianos PK et al. | β | 2026 | β |
| Accurate detection of somatic single-nucleotide variants from bulk RNA-seq data using RNA-MosaicHunter. | Huang AY et al. | β | 2026 | β |
| Analysis of genetic mutation characteristics in 40 Chinese patients with hepatocellular carcinoma. | Xu S et al. | β | 2026 | β |
| Analysis of Somatic Mutations and Immunotherapy Biomarkers in Chinese Patients With Non-Small Cell Lung Cancer During 2019-2024: A Retrospective Study. | Liu X et al. | β | 2026 | β |
| A Patient-Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery. | Zhang H et al. | β | 2026 | β |
| A single next generation sequencing assay for detection of driver mutations, rearrangements and copy number abnormalities in plasma cell dyscrasias. | Bonolo de Campos C et al. | β | 2026 | β |
| Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. | Kong T et al. | β | 2026 | β |
| Cancer evolution and multi-omic profile of relapsed colorectal liver metastases after treatment. | TomΓ‘s L et al. | β | 2026 | β |
| Cerebrospinal fluid cfDNA-based molecular assessment of resection extent and prognosis in glioma. | Wu J et al. | β | 2026 | β |
| Characterization of subclonal variants in HG002 Genome in a Bottle reference material as a resource for benchmarking variant callers. | Daniels CA et al. | β | 2026 | β |
| Chemotherapy-free cancer treatment - not for everyone yet. | DonzΓ© C et al. | β | 2026 | β |
| Chromosome 15q15 Deletion Drives Brain Metastasis in NSCLC. | Miyakoshi J et al. | β | 2026 | β |
| Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag. | Kaya DE et al. | β | 2026 | β |
| Clonal haematopoiesis of indeterminate potential and risk of incident psychiatric disorders. | Yu Y et al. | β | 2026 | β |
| Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial. | Xue L et al. | β | 2026 | β |
| Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort. | Regan JA et al. | β | 2026 | β |
| Clonal hematopoiesis is associated with future diseases and mortality. | Liu W et al. | β | 2026 | β |
| Comprehensive analysis reveals the molecular heterogeneity and the differences in prognosis and immunotherapy sensitivity in hypermutated colorectal cancer. | Bai G et al. | β | 2026 | β |
| Deciphering the genetic underlying causes of sex differences in multiple myeloma incidence and mortality. | Opakunle A et al. | β | 2026 | β |
| Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor. | Fleming AM et al. | β | 2026 | β |
| Divergent evolution of hepatocellular carcinoma genomes in chimpanzees and humans. | Kang L et al. | β | 2026 | β |
| Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R. | Yang Y et al. | β | 2026 | β |
| Ecology and demographic structure of an extinct ibex population in late Upper Palaeolithic Italian Alps. | Armaroli E et al. | β | 2026 | β |
| ERBB2 amplification is a late event in the pathogenesis of high-grade endometrial carcinomas with heterogeneous HER2 expression. | Chui MH et al. | β | 2026 | β |
| Exome sequencing of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common founding precursors. | Gomez F et al. | β | 2026 | β |
| Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis. | Moreno-CΓ‘rdenas AB et al. | β | 2026 | β |
| Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer. | Poturnajova M et al. | β | 2026 | β |
| Genetic landscape of pediatric acute myeloid leukemia in Taiwan. | Cheng Z et al. | β | 2026 | β |
| Genomic and transcriptomic analyses of melanoma in Japanese patients reveal candidate biomarkers for immune checkpoint inhibitor responders. | Kimura T et al. | β | 2026 | β |
| Genomic characterization and prognosis of pancreatic adenosquamous carcinoma. | Huang Y et al. | β | 2026 | β |
| Genomic, phenomic and geographic associations of leukocyte telomere length in the United States. | Nakao T et al. | β | 2026 | β |
| Genomic profiling reveals molecular heterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL). | Tian S et al. | β | 2026 | β |
| Haplotype-aware segmentation with HapASeg increases accuracy of detecting homolog-specific somatic copy number alterations. | Priebe O et al. | β | 2026 | β |
| Homologous recombination deficiency and hemizygosityΒ drive resistance in breast cancer. | Safonov A et al. | β | 2026 | β |
| Immunopeptidomics combined with full-length transcriptomics uncovers diverse neoantigens. | Ishino T et al. | β | 2026 | β |
| Insertional activity of human Alu and L1 retrotransposons is associated with DNA repair pathways and genome instability in cancer. | Suntsova M et al. | β | 2026 | β |
| Integrated clinical and molecular landscape of disseminated pediatric low-grade glioma. | Levine AB et al. | β | 2026 | β |
| Intra-Leukemic Interferon Signaling Suppresses Expansion and Mediates Chemoresistance in Human AML. | Karigane D et al. | β | 2026 | β |
| Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. | Chaudhary R et al. | β | 2026 | β |
| <i>mtDNApipe</i>: A Pioneering Pipeline for High-Sensitivity Detection of Low-Frequency Mitochondrial DNA Mutations. | Guo W et al. | β | 2026 | β |
| Mapping Genomic Heterogeneity in Pediatric and Adolescent-Young Adult Sarcomas: Insights from the Italian SAR-GEN2016 and SAR-GEN_ITA Prospective Multicenter Trials. | Tirtei E et al. | β | 2026 | β |
| Microglandular adenosis, triple negative breast carcinoma and DNA repair defects. | Bedell M et al. | β | 2026 | β |
| Mitochondrial heteroplasmy is a risk factor for the development of chronic lymphocytic leukemia. | Pasca S et al. | β | 2026 | β |
| MobiCT: a UMI-based circulating tumor DNA analysis pipeline. | Cabello-Aguilar S et al. | β | 2026 | β |
| Multi-omics integration defines an ECM-associated intratumoral heterogeneity signature enabling prognosis assessment and therapeutic stratification in hepatocellular carcinoma. | Liu T et al. | β | 2026 | β |
| Pipe dream to pipeline: Journey of cancer vaccines and the road ahead. | Onkar S et al. | β | 2026 | β |
| Predominant mutated non-canonical tumor-specific antigens identified by proteogenomics demonstrate immunogenicity and tumor suppression in CRC. | Xiang H et al. | β | 2026 | β |
| Primary pulmonary Langerhans cell histiocytosis: comprehensive clinicopathologic and molecular genetic analysis of 13 cases. | Zhang Y et al. | β | 2026 | β |
| PTPN11-related Noonan syndrome predisposes to multifocal low-grade CNS tumors harboring FGFR1 variants. | Kohanbash G et al. | β | 2026 | β |
| Red Blood Cells Internalize Extracellular DNA via Apoptotic Bodies with Clinical Relevance to Cancer Patients. | Zeng Z et al. | β | 2026 | β |
| Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and <i>BAP1</i> loss. | Camp SY et al. | β | 2026 | β |
| Somatic mutations distinguish melanocyte subpopulations in human skin. | Tandukar B et al. | β | 2026 | β |
| Somatic structural variants drive upper tract urothelial carcinoma muscle invasiveness via activation of TPX2 transcription. | Xu Z et al. | β | 2026 | β |
| Targeting cancer stem cells predicts response and reverses chemoresistance in ascites-derived ovarian cancer organoids. | Zhang X et al. | β | 2026 | β |
| The Landscape of CEACAM5 Expression by Immunohistochemistry in NSCLC. | Hsu YR et al. | β | 2026 | β |
| Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer. | Nishizaki D et al. | β | 2026 | β |
| Whole-Genome Deep Learning Predicts Chemotherapy Response in Colorectal Cancer. | Sadeghi H et al. | β | 2026 | β |
| Whole-genome landscapes of 1,364 breast cancers. | Kim R et al. | β | 2026 | β |
| Accurate somatic small variant discovery for multiple sequencing technologies with DeepSomatic. | Park J et al. | β | 2025 | β |
| A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy. | Maurer K et al. | β | 2025 | β |
| A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer. | Nauseef JT et al. | β | 2025 | β |
| A Comprehensive Bioinformatics Approach to Analysis of Variants: Variant Calling, Annotation, and Prioritization. | Koroglu MN et al. | β | 2025 | β |
| A Comprehensive Guide to Achieving New York State Clinical Laboratory Evaluation Program Approval for Next-Generation Sequencing Assays. | Galbo PM et al. | β | 2025 | β |
| A comprehensive pan-cancer analysis of LRFN4: its potential as a prognostic biomarker and therapeutic target for immunotherapy. | Xu Y et al. | β | 2025 | β |
| A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. | Huber F et al. | β | 2025 | β |
| Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials. | AndrΓ© F et al. | β | 2025 | β |
| Adenomas from individuals with pathogenic biallelic variants in the MUTYH and NTHL1 genes demonstrate base excision repair tumour mutational signature profiles similar to colorectal cancers, expanding potential diagnostic and variant classification applications. | Walker R et al. | β | 2025 | β |
| Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial. | Galsky MD et al. | β | 2025 | β |
| Aldh2 and the tumor suppressor Trp53 play important roles in alcohol-induced squamous field cancerization. | Kondo Y et al. | β | 2025 | β |
| A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma. | Blass E et al. | β | 2025 | β |
| A Multi-Center Real-World Study of Clinicopathologic Characteristics and Efficacy of the Malignant Mesothelioma in Chinese Population. | Sun C et al. | β | 2025 | β |
| Analysis of germline-somatic mutational connections in colorectal cancer reveals differential tumorigenic patterns and a novel predictive marker for germline mutation carriers. | Li M et al. | β | 2025 | β |
| Analysis of the molecular subtypes and prognostic models of anoikis-related genes in colorectal cancer. | Shen L et al. | β | 2025 | β |
| Analysis of Variants Induced by Combined Ex Vivo Irradiation and In Vivo Tumorigenesis Suggests a Role for the ZNF831 p.R1393Q Variant in Cutaneous Melanoma Development. | Usoltsev D et al. | β | 2025 | β |
| A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. | Braun DA et al. | β | 2025 | β |
| Angiogenesis gene signatures in patient-derived tumor spheroids for genetic and tumor angiogenesis profiling. | Hyung S et al. | β | 2025 | β |
| An optimized tissue sampling scheme guided by MRI features reveals intratumoral heterogeneity in glioblastoma. | Wang JH et al. | β | 2025 | β |
| Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial. | Yi C et al. | β | 2025 | β |
| A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001). | Chen HJ et al. | β | 2025 | β |
| APOBEC3 mutagenesis drives therapy resistance in breast cancer. | Gupta A et al. | β | 2025 | β |
| A population-based analysis of the molecular landscape of glioma in adolescents and young adults reveals insights into gliomagenesis. | Bennett J et al. | β | 2025 | β |
| A set cover algorithm identifies minimal circulating tumour DNA sequencing targets for colorectal cancer detection. | Moloney-Geany K et al. | β | 2025 | β |
| Assessing individual head and neck squamous cell carcinoma patient response to therapy through integration of functional and genomic data. | Bottomly D et al. | β | 2025 | β |
| Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients. | Nguyen HB et al. | β | 2025 | β |
| Association of clonal hematopoiesis of indeterminate potential with cardiometabolic multimorbidity progression and mortality: a prospective study of UK Biobank. | Zuo C et al. | β | 2025 | β |
| A stem cell differentiation model reveals two alternative fates in CBFA2T3::GLIS2-driven acute megakaryoblastic leukemia initiation. | Shoeb MR et al. | β | 2025 | β |
| Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of Cancers. | Jackson JC et al. | β | 2025 | β |
| Cancer genomics and bioinformatics in Latin American countries: applications, challenges, and perspectives. | Torres-Narvaez ES et al. | β | 2025 | β |
| CanSeer: a translational methodology for developing personalized cancer models and therapeutics. | Butt RN et al. | β | 2025 | β |
| CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib. | Huang Y et al. | β | 2025 | β |
| Cellulose microfiber-mediated mesoscale architecture promotes the expansion of patient-derived lung cancer organoids while preserving their malignant characteristics. | Zhou C et al. | β | 2025 | β |
| Characterization of Extrachromosomal Circular DNA in Primary and Cisplatin-Resistant High-Grade Serous Ovarian Cancer. | Wang Y et al. | β | 2025 | β |
| Characterization of the genomic landscape in liver oligometastatic NSCLC. | Liao R et al. | β | 2025 | β |
| Characterizing the mutational landscape of sinonasal squamous cell carcinoma using whole-exome sequencing. | Vareta JA et al. | β | 2025 | β |
| Circulating human papillomavirus DNA sequencing as a biomarker of response in advanced cervical cancer. | Collier E et al. | β | 2025 | β |
| Circulating tumor-reactive KIR<sup>+</sup>CD8<sup>+</sup> Tβcells suppress anti-tumor immunity in patients with melanoma. | Lu BY et al. | β | 2025 | β |
| Clinical Impact and Genomic Features of Human Epidermal Growth Factor Receptor 2-Low Tumors in <i>BRCA1/2</i>-Mutated Triple-Negative Breast Cancer. | Kou F et al. | β | 2025 | β |
| Clinical utility of genome sequencing in rare diseases: lessons from a single-center study of 1,452 Korean families. | Lee S et al. | β | 2025 | β |
| Clinicopathological features and genetic mutation spectrum of primary anastomosing hemangioma arising from the kidney. | Zhang L et al. | β | 2025 | β |
| Clonal diversity shapes the tumour microenvironment leading to distinct immunotherapy responses in metastatic urothelial carcinoma. | Kamatani T et al. | β | 2025 | β |
| Clonal hematopoiesis of indeterminate potential and incidence of venous thromboembolism in older adults. | Saadatagah S et al. | β | 2025 | β |
| Clonal Hematopoiesis of Indeterminate Potential and Risk of Microvascular Complications Among Individuals With Type 2 Diabetes: A Cohort Study. | Wei J et al. | β | 2025 | β |
| Clonal hematopoiesis of indeterminate potential and the risk of autoimmune diseases. | Wu H et al. | β | 2025 | β |
| Clonal Hematopoiesis of Indeterminate Potential Associated with Covert Cerebral Changes. | Li Y et al. | β | 2025 | β |
| Clonal hematopoiesis of indeterminate potential, health indicators, and risk of cardiovascular diseases among patients with diabetes: a prospective cohort study. | Sun Y et al. | β | 2025 | β |
| Colorectal Tumors in Diverse Patient Populations Feature a Spectrum of Somatic Mutational Profiles. | Matejcic M et al. | β | 2025 | β |
| Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer. | Zhou D et al. | β | 2025 | β |
| Comparative analysis of the Mexico City Prospective Study and the UK Biobank identifies ancestry-specific effects on clonal hematopoiesis. | Wen S et al. | β | 2025 | β |
| Comparative Evaluation of Mutect2, Strelka2, and FreeBayes for Somatic SNV Detection in Synthetic and Clinical Whole-Exome Sequencing Data. | LΓ³pez-Cade I et al. | β | 2025 | β |
| Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA. | CarriΓ© H et al. | β | 2025 | β |
| Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma. | Gao J et al. | β | 2025 | β |
| Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes. | Arenillas C et al. | β | 2025 | β |
| Crowd-sourced benchmarking of single-sample tumor subclonal reconstruction. | Salcedo A et al. | β | 2025 | β |
| Current Bioinformatics Tools in Precision Oncology. | Wolde T et al. | β | 2025 | β |
| Cytologic, histologic, and clinical correlation of minor mutations in pancreatic cysts. | Kwan MC et al. | β | 2025 | β |
| Decoding intertumoral heterogeneity in multifocal ground-glass nodule lung cancers: Clonal evolutionary insight for precision management. | Xie CL et al. | β | 2025 | β |
| Decorin as a key marker of desmoplastic cancer-associated fibroblasts mediating first-line immune checkpoint blockade resistance in metastatic gastric cancer. | Kim KT et al. | β | 2025 | β |
| Defining APOBEC-induced mutation signatures and modifying activities in yeast. | Mertz TM et al. | β | 2025 | β |
| Depletion of regulatory T cells enhances the T cell response induced by the neoantigen vaccine with weak immunogenicity. | Huang R et al. | β | 2025 | β |
| Detecting somatic variants in purified brain DNA obtained from surgically implanted depth electrodes in epilepsy. | Mascarenhas R et al. | β | 2025 | β |
| Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA. | Parsons HA et al. | β | 2025 | β |
| Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial. | Lim SH et al. | β | 2025 | β |
| Development and characterization of orthotopic patient-derived xenograft models of peritoneal metastatic mucinous appendiceal adenocarcinoma. | Ito I et al. | β | 2025 | β |
| Development and validation of a molecular classifier of meningiomas. | Landry AP et al. | β | 2025 | β |
| Development of a multi-neoepitope vaccine targeting non-small cell lung cancer through reverse vaccinology and bioinformatics approaches. | Asadollahi E et al. | β | 2025 | β |
| Digital sequencing is improved by using structured unique molecular identifiers. | Micallef P et al. | β | 2025 | β |
| Direct and indirect effects of multiplex genome editing of F5H and FAD2 in oil crop camelina. | van Belle J et al. | β | 2025 | β |
| DirectHRD enables sensitive scar-based classification of homologous recombination deficiency. | Liu R et al. | β | 2025 | β |
| Discovery of Cis-Regulatory Mechanisms via Non-Coding Mutations in Acute Lymphoblastic Leukemia. | AydΔ±n E et al. | β | 2025 | β |
| Distinct genomic subgroups and mutational patterns in undifferentiated/dedifferentiated endometrial carcinoma. | Huang CY et al. | β | 2025 | β |
| DTC-Flow: a flow cytometry-based detection platform for characterizing bone marrow disseminated tumor cells in breast cancer. | Chislock EM et al. | β | 2025 | β |
| Early separation and parallel clonal selection of dedifferentiated and well-differentiated components in dedifferentiated liposarcoma. | Sekita T et al. | β | 2025 | β |
| Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations. | Varadarajan K et al. | β | 2025 | β |
| Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial. | Waks AG et al. | β | 2025 | β |
| Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial. | Ge T et al. | β | 2025 | β |
| Eliciting antitumor immunity via therapeutic cancer vaccines. | Peng K et al. | β | 2025 | β |
| Endometrial tumorigenesis involves epigenetic plasticity demarcating non-coding somatic mutations and 3D-genome alterations. | Gregoricchio S et al. | β | 2025 | β |
| Enhancing oil feedstock utilization for high-yield low-carbon polyhydroxyalkanoates industrial bioproduction. | Jiang T et al. | β | 2025 | β |
| Establishing a cryopreserved biobank of living tumor tissues for drug sensitivity testing. | Chen P et al. | β | 2025 | β |
| Establishment and characterization of novel cancer cachexia-inducing cell line, Aku60GC, of scirrhous gastric cancer. | Noguchi R et al. | β | 2025 | β |
| Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening. | Cui R et al. | β | 2025 | β |
| Evaluating Discordant Somatic Calls Across Mutation Discovery Approaches to Minimize False-Negative Drug-Resistant Findings. | Lin HF et al. | β | 2025 | β |
| Evidence of DNA methylation heterogeneity and epipolymorphism in kidney cancer tissue samples. | Rossi SH et al. | β | 2025 | β |
| Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma. | Barroux M et al. | β | 2025 | β |
| Evolutionary unpredictability in cancer model systems. | Chattopadhyay S et al. | β | 2025 | β |
| Extremely early genomic events and temporal order of esophageal squamous cell carcinogenesis: Longitudinal self-comparison of progressors and non-progressors. | Liu Y et al. | β | 2025 | β |
| From ideal to practical: Heterogeneity of student-generated variant lists highlights hidden reproducibility gaps. | ErtΓΌrk RA et al. | β | 2025 | β |
| Functional screening of somatic mutant events in extranodal natural killer/T-cell lymphoma with adrenal involvement. | Zhang L et al. | β | 2025 | β |
| Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors. | Welte T et al. | β | 2025 | β |
| Gene profiling and clinicopathological features for prognostic modeling of recurrence in non-metastatic clear-cell renal cell carcinoma. | Yan X et al. | β | 2025 | β |
| Genetic determinants and genomic consequences of non-leukemogenic somatic point mutations. | Weinstock JS et al. | β | 2025 | β |
| Genetic heterogeneity and key driver mutations in the preneoplastic and earliest stages of gastric cancer. | MarroquΓn-Estrada EA et al. | β | 2025 | β |
| Genetic landscape of non-UV-induced cutaneous squamous cell carcinomas. | Al Youssef C et al. | β | 2025 | β |
| Genetic Subtype-Based International Prognostic Index Prognostic Model in Diffuse Large B-Cell Lymphoma. | Mi L et al. | β | 2025 | β |
| Genomic alterations and transcriptional phenotypes in circulating free DNA and matched metastatic tumor. | Takahashi N et al. | β | 2025 | β |
| Genomic and clinical insights into ovarian cancer: subtype-specific alterations and predictors of metastasis and relapse. | Cheng F et al. | β | 2025 | β |
| Genomic and DNA methylomic factors associated with the efficacy of oral medroxyprogesterone acetate on endometrial neoplastic disease. | Sugiyama Y et al. | β | 2025 | β |
| Genomic and Transcriptomic Landscape of Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma: A Multicenter Study. | Li Y et al. | β | 2025 | β |
| Genomic characterization of colorectal tumors: insights into significantly mutated genes, pathways, and survival outcomes. | Harrison TA et al. | β | 2025 | β |
| Genomic, Epigenomic, and Transcriptomic Inter- and Intratumor Heterogeneity in Desmoid Tumors. | De Bellis C et al. | β | 2025 | β |
| Genomic landscape of multiple myeloma and its precursor conditions. | Alberge JB et al. | β | 2025 | β |
| Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. | Schiantarelli J et al. | β | 2025 | β |
| Genomic Profiles of Pathogenic and Moderate-Penetrance Germline Variants Associated With Risk of Early-Onset Lung Adenocarcinoma. | Cho H et al. | β | 2025 | β |
| Genomic profiling of circulating tumor DNA for childhood cancers. | Lei S et al. | β | 2025 | β |
| Genomics-led approach to drug testing in models of undifferentiated pleomorphic sarcoma. | Manasterski PJ et al. | β | 2025 | β |
| Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy. | Liu J et al. | β | 2025 | β |
| Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition. | Fiorica PN et al. | β | 2025 | β |
| Germline predisposition in multiple myeloma. | Martins Rodrigues F et al. | β | 2025 | β |
| Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer. | Yazaki S et al. | β | 2025 | β |
| Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression. | Blomquist MR et al. | β | 2025 | β |
| Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer. | Grassi E et al. | β | 2025 | β |
| High Tumor Mutation Burden (TMB) and a Novel Somatic Mutation in the TREX1 Gene in a Patient with Aggressive and Refractory High-Grade B-Cell Lymphoma: A Case Report. | Gusakova M et al. | β | 2025 | β |
| HNF1A-inactived Hepatocellular Adenomas in Fibropolycystic Kidney and Liver Disease Are Associated With Germline HNF1B Variant. | Hagen CE et al. | β | 2025 | β |
| Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with β€5 conventional imaging defined distant metastases. | Pan J et al. | β | 2025 | β |
| Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer. | Comino-MΓ©ndez I et al. | β | 2025 | β |
| Identification of the Lynch syndrome and Lynch-like syndrome specific somatic mutations in microsatellite instability-high colorectal cancer cases. | Ofuchi T et al. | β | 2025 | β |
| Illuminating the Noncoding Genome in Cancer Using Artificial Intelligence. | Alvarez-Torres MDM et al. | β | 2025 | β |
| Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial. | Goswami S et al. | β | 2025 | β |
| Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. | Jammihal T et al. | β | 2025 | β |
| Improved identification of tumor-specific TCRs from circulating lymphocytes using autologous colorectal tumor organoids. | Ma L et al. | β | 2025 | β |
| Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial. | Weathers SP et al. | β | 2025 | β |
| Incident cytopenia and risk of subsequent myeloid neoplasm in age-related clonal hematopoiesis: a multi-biobank case-control study. | Brogan J et al. | β | 2025 | β |
| Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors. | Ma J et al. | β | 2025 | β |
| Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy. | Peng T et al. | β | 2025 | β |
| Induced somatic mutation accumulation during skeletal muscle regeneration reduces muscle strength. | VrtaΔnik P et al. | β | 2025 | β |
| Insight into the Relationship between Congenital Large/Giant Melanocytic Nevi and Satellite Nevi. | Gu J et al. | β | 2025 | β |
| Integrated Analysis of Somatic DNA Variants and DNA Methylation of Tumor Suppressor Genes in Colorectal Cancer. | Nishiki H et al. | β | 2025 | β |
| Integrated genomic analysis of NF1-associated peripheral nerve sheath tumors: an updated biorepository dataset. | Banerjee J et al. | β | 2025 | β |
| Integrated molecular and detailed anatomical profiling identifies a prognostically adverse subtype of posterior fossa meningiomas: high-risk copy number alterations are associated with midline predilection and predict poor prognosis. | Hirano Y et al. | β | 2025 | β |
| Integrated Multi-Omics Profiling to Characterize Molecular Subtypes and Reveal Potential Therapeutic Strategies for Colorectal Cancer. | Guo X et al. | β | 2025 | β |
| Integrated Multiomics Validation of Key <i>MUC</i> Gene Expression for the Signature Biomarker in the Pakistani Cohort. | Naeem M et al. | β | 2025 | β |
| Integrated proteogenomic characterization of ampullary adenocarcinoma. | Zhang Q et al. | β | 2025 | β |
| Integrating functional proteomics and next generation sequencing reveals potential therapeutic targets for Taiwanese breast cancer. | Ku WC et al. | β | 2025 | β |
| Integration of scRNA-Seq and scATAC-Seq Reveals Malignant Characteristics of Sarcomatoid Clear Cell Renal Cell Carcinoma. | Lu W et al. | β | 2025 | β |
| Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma. | Bergsma P et al. | β | 2025 | β |
| Intrahepatic Microbial Heterogeneity in Multifocal Hepatocellular Carcinoma and Its Association with Host Genomic and Transcriptomic Alterations. | Lu Y et al. | β | 2025 | β |
| In vivo functional screens reveal <i>KEAP1</i> loss as a driver of chemoresistance in small cell lung cancer. | Brumage L et al. | β | 2025 | β |
| IRF4 Promotes Immune Evasion and Shapes the Tumor Microenvironment in Follicular Lymphoma. | Dasari S et al. | β | 2025 | β |
| Is <i>Candida albicans</i> a promoting factor, rather than an inducing factor for oral cancer? | Wang X et al. | β | 2025 | β |
| Isolation and Characterization of the Adamantinomatous Craniopharyngioma Primary Cells with Cancer-Associated Fibroblast Features. | Chen D et al. | β | 2025 | β |
| Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment. | Crisafulli G | β | 2025 | β |
| Liquid Biopsy for Enhanced Specificity in Identifying Somatic Mutations in Aggressive Non-Hodgkin Large B-Cell Lymphoma: A Comparative Study of Cell-Free DNA and Formalin-Fixed Paraffin-Embedded Tissue. | Vimalathas G et al. | β | 2025 | β |
| Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA. | Riviere-Cazaux C et al. | β | 2025 | β |
| Lossless and reference-free compression of FASTQ/A files using GeneSqueeze. | Nazari F et al. | β | 2025 | β |
| Low T cell diversity associates with poor outcome in bladder cancer: A comprehensive longitudinal analysis of the T cell receptor repertoire. | KjΓ¦r A et al. | β | 2025 | β |
| Machine learning-driven prognostic and diagnostic models for lung adenocarcinoma using intratumor heterogeneity and multi-omics data. | Li X et al. | β | 2025 | β |
| Malignant Giant Cell Tumor of Bone: A Clinicopathologic Series of 28 Cases Highlighting Genetic Differences Compared With Conventional, Atypical, and Metastasizing Conventional Tumors. | Papke DJ et al. | β | 2025 | β |
| Mapping the chromothripsis landscape in urothelial carcinoma unravels great intratumoral and intertumoral heterogeneity. | Zeng Y et al. | β | 2025 | β |
| Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response. | Skelly DA et al. | β | 2025 | β |
| Mesenchymal stromal cells promote the formation of lung cancer organoids via Kindlin-2. | Sui Z et al. | β | 2025 | β |
| Microbiome analysis of 940 lung cancers in never-smokers reveals lack of clinically relevant associations. | McElderry JP et al. | β | 2025 | β |
| Molecular and immune determinants of response in locally advanced deficient DNA mismatch repair/microsatellite instability-high gastric or gastroesophageal junction adenocarcinoma treated with neoadjuvant chemoimmunotherapy. | Yu P et al. | β | 2025 | β |
| Molecular characterization of colorectal cancer (CRC) using next generation sequencing (NGS) in bridging the gap between research and clinical practice: from biomarker discovery to clinical implementation. | Afolabi HA et al. | β | 2025 | β |
| Molecular Characterization of Oral Squamous Cell Carcinoma in Mexican Patients: A Genomic and Epidemiological Overview. | Lopez-Gomez J et al. | β | 2025 | β |
| Molecular Classification of Endometrial Cancers Using an Integrative DNA Sequencing Panel. | Kim SR et al. | β | 2025 | β |
| Molecular insights into prognostic model for meningiomas treated with stereotactic radiosurgery: negative impacts of 1q gain on tumor control and survival. | Umekawa M et al. | β | 2025 | β |
| Molecular signals associated with intraperitoneal chemotherapy resistance in gastric cancer with peritoneal metastasis through PIPS GC trial integrated translational research. | Seo WJ et al. | β | 2025 | β |
| Molecular Tumor Board-Guided Targeted Treatments for Biliary Tract Cancers in a Publicly Funded Healthcare System. | Beaudry FEG et al. | β | 2025 | β |
| Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics. | Vimalathas G et al. | β | 2025 | β |
| MorphoITH: a framework for deconvolving intra-tumor heterogeneity using tissue morphology. | Nielsen AW et al. | β | 2025 | β |
| Mosaic variants of neurodevelopmental and mitochondrial genes in postmortem paraventricular thalamus in bipolar disorder detected by deep exome sequencing. | Nishioka M et al. | β | 2025 | β |
| MOV&RSim: computational modelling of cancer-specific variants and sequencing reads characteristics for realistic tumoral sample simulation. | Longhin F et al. | β | 2025 | β |
| Multi-analyte approach combining cfDNA sequencing and protein testing for early ovarian cancer detection. | Wang F et al. | β | 2025 | β |
| Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles. | Flynn A et al. | β | 2025 | β |
| Multiomic quantification of the KRAS mutation dosage improves the preoperative prediction of survival and recurrence in patients with pancreatic ductal adenocarcinoma. | Yun WG et al. | β | 2025 | β |
| Multiβomics analysis identifies different molecular subtypes with unique outcomes in early-stage poorly differentiated lung adenocarcinoma. | Liu B et al. | β | 2025 | β |
| Multiomic Sequencing of Intermediate- to High-Risk Cutaneous Squamous Cell Carcinoma Identifies Critical Genes and Expression Patterns Associated with Disease and Poor Outcomes. | Nassir S et al. | β | 2025 | β |
| Multi-omics sequencing of gastroesophageal junction adenocarcinoma reveals prognosis-relevant key factors and a novel immunogenomic classification. | Ma Z et al. | β | 2025 | β |
| Multi-scale cancer driver gene prediction by flexible data selection and network topology guidance. | Liu J et al. | β | 2025 | β |
| Mutational landscape of triple-negative breast cancer in African American women. | Yao S et al. | β | 2025 | β |
| Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities. | Nukaga S et al. | β | 2025 | β |
| Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma. | Cai Y et al. | β | 2025 | β |
| Neoantigen load as a predictor of relapse in early-stage NSCLC: features that agonise and antagonise prognosis. | Ye L et al. | β | 2025 | β |
| Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. | Lowery FJ et al. | β | 2025 | β |
| New insights into the genetic progression of cancer through longitudinal analysis of oral lesions. | Wils LJ et al. | β | 2025 | β |
| N-glycans in lung tissue specimens: a prospective target for enhanced cancer diagnosis and prognosis. | Lattova E et al. | β | 2025 | β |
| Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. | Shitara K et al. | β | 2025 | β |
| Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence. | Soeung M et al. | β | 2025 | β |
| Non-recurrent mutations and copy number changes predominate pituitary adenoma genomes. | Mohan DR et al. | β | 2025 | β |
| Novel kinase-activating genetic events in non-small cell lung carcinomas. | Preobrazhenskaya EV et al. | β | 2025 | β |
| OmniNeo: a multi-omics pipeline incorporating proteomics and AI selection for neoantigen optimization in tumor immunotherapy. | Lu M et al. | β | 2025 | β |
| Oncogenic pathway landscape of ovarian cancer and correlation with clinical prognosis. | Lee YJ et al. | β | 2025 | β |
| Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. | Li R et al. | β | 2025 | β |
| Optimizing the NGS-based discrimination of multiple lung cancers from the perspective of evolution. | Wang Z et al. | β | 2025 | β |
| Panoramic spatial enhanced resolution proteomics (PSERP) reveals tumor architecture and heterogeneity in gliomas. | Xu Z et al. | β | 2025 | β |
| Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. | Yin X et al. | β | 2025 | β |
| Patient-Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing PersonalizedΒ Treatment. | Zhao H et al. | β | 2025 | β |
| Patient-derived esophageal adenocarcinoma organ chip: a physiologically relevant platform for functional precision oncology. | Pal S et al. | β | 2025 | β |
| Patient-derived organoid-guided precision therapy for a very young woman with multidrug-resistant metastatic breast cancer: a case report. | Zhang X et al. | β | 2025 | β |
| Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening. | Qian J et al. | β | 2025 | β |
| Patritumab deruxtecan in HR<sup>+</sup>HER2<sup>-</sup> advanced breast cancer: a phase 2 trial. | Pistilli B et al. | β | 2025 | β |
| Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies. | Lee HJ et al. | β | 2025 | β |
| Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer. | Roudier MP et al. | β | 2025 | β |
| PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC. | Miyakoshi J et al. | β | 2025 | β |
| Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. | Rini BI et al. | β | 2025 | β |
| Pharmacological rescue of mutant p53 triggers spontaneous tumor regression via immune responses. | Li J et al. | β | 2025 | β |
| Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal. | Morris VK et al. | β | 2025 | β |
| Precise detection of differential RNA editing sites across varied biological conditions using the CADRES pipeline. | Sun J et al. | β | 2025 | β |
| Predictive model for prognosis, immune microenvironment and drug sensitivity of colon carcinoma based on cuproptosis-related genes. | Zhao B et al. | β | 2025 | β |
| Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinib. | Torres-Cabala CA et al. | β | 2025 | β |
| Primary mucinous cystadenocarcinoma of the breast: A case report and literature review. | Cao X et al. | β | 2025 | β |
| Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets. | Felsheim BM et al. | β | 2025 | β |
| Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups. | Ji S et al. | β | 2025 | β |
| Proteogenomic characterization reveals that lipid droplet formation promotes esophageal squamous cell cancer progression. | Qin Z et al. | β | 2025 | β |
| Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. | Holt MV et al. | β | 2025 | β |
| Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer. | BΓΆrcsΓΆk J et al. | β | 2025 | β |
| Racial variation in the advanced prostate cancer genome. | Feng EM et al. | β | 2025 | β |
| Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer. | Zenga J et al. | β | 2025 | β |
| Rare germline variants in cancer-relevant genes are associated with breast cancer risk in young women with high-risk family history. | Rozenblit M et al. | β | 2025 | β |
| Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection. | Campanella G et al. | β | 2025 | β |
| Receptor tyrosine kinase inhibitor tivozanib regulates cell state plasticity and restores MITF dependency in BRAF wild-type melanoma. | Ma YN et al. | β | 2025 | β |
| Recurrent hepatocellular carcinoma is associated with the enrichment of MYC targets gene sets, elevated high confidence deleterious mutations and alternative splicing of DDB2 and BRCA1 transcripts. | KaraosmanoΔlu O | β | 2025 | β |
| Refined Procedure to Purify and Sequence Circulating Cell-Free DNA in Prostate Cancer. | Rahimirad S et al. | β | 2025 | β |
| Risk of clonal hematopoiesis in families exposed to radiation following the Chornobyl accident. | Machiela MJ et al. | β | 2025 | β |
| RNA neoantigen vaccines prime long-lived CD8<sup>+</sup> T cells in pancreatic cancer. | Sethna Z et al. | β | 2025 | β |
| RNA sequencing enables neoantigen discovery and vaccine validation in breast and lung cancer. | Hu H et al. | β | 2025 | β |
| Scaling for African Inclusion in High-Throughput Whole Cancer Genome Bioinformatic Workflows. | Jiang J et al. | β | 2025 | β |
| Secretory breast carcinoma: morphologic and molecular heterogeneity with indicators of aggressive potential in a cohort of 29 cases. | Ren H et al. | β | 2025 | β |
| Sequential omics analysis reveals molecular signatures of malignant transformation in recurrent meningiomas. | Ohara K et al. | β | 2025 | β |
| Single-cell profiling identifies biomarkers for immunochemotherapy in esophageal squamous cell carcinoma. | Wang C et al. | β | 2025 | β |
| Single-Cell Profiling of Pediatric High-Grade Gliomas Reveals OPC-Like Subpopulations Driving Tumorigenic Lineage Transitions. | Tian T et al. | β | 2025 | β |
| Single-Cell RNA Sequencing of Ewing Sarcoma Tumors Demonstrates Transcriptional Heterogeneity and Clonal Evolution. | Goodspeed A et al. | β | 2025 | β |
| Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma. | Sam I et al. | β | 2025 | β |
| Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival. | Talbot J et al. | β | 2025 | β |
| Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis. | Ong CJ et al. | β | 2025 | β |
| Spatially Discontinuous Mutation Topographies in Ductal Carcinoma In Situ Reveal Noncompetitive Growth Dynamics. | Ryser MD et al. | β | 2025 | β |
| Spatial-Temporal Diversity of Extrachromosomal DNA Shapes Urothelial Carcinoma Evolution and the Tumor Immune Microenvironment. | Lv W et al. | β | 2025 | β |
| Spatial-Temporal Diversity of Extrachromosomal DNA Shapes Urothelial Carcinoma Evolution and Tumor-Immune Microenvironment. | Lv W et al. | β | 2025 | β |
| Stratification by Mutational Landscape Reveals Differential Immune Infiltration and Predicts the Recurrence and Clinical Outcome of Cervical Cancer. | Gao C et al. | β | 2025 | β |
| Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients. | Nie X et al. | β | 2025 | β |
| Systemic inflammation biomarkers can identify high tumor mutation burden in lung adenocarcinoma. | Fang J et al. | β | 2025 | β |
| Tamoxifen induces PI3K activation in uterine cancer. | KΓΌbler K et al. | β | 2025 | β |
| Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel. | Lee S et al. | β | 2025 | β |
| Targeting Mesothelin Enhances Personalized Neoantigen Vaccine Induced Antitumor Immune Response in Orthotopic Pancreatic Cancer Mouse Models. | Cai Z et al. | β | 2025 | β |
| Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer. | Sun X et al. | β | 2025 | β |
| TET2 gene mutation status associated with poor prognosis of transition zone prostate cancer: a retrospective cohort study based on whole exome sequencing and machine learning models. | Wang Y et al. | β | 2025 | β |
| TET2-mutant myeloid cells mitigate Alzheimer's disease progression via CNS infiltration and enhanced phagocytosis in mice. | Matatall KA et al. | β | 2025 | β |
| The Association Between Thyroid Differentiation Score and Survival Outcomes in Papillary Thyroid Carcinoma. | Wang JR et al. | β | 2025 | β |
| The Cancer Genome in the Long Reads Era. | Ermini L | β | 2025 | β |
| The Evolutionary Forest of Pancreatic Cancer. | Mullen KM et al. | β | 2025 | β |
| The genetic landscape of primary malignant melanoma of the cervix using integrated bioinformatics analysis and whole-exome sequencing. | Zhou J et al. | β | 2025 | β |
| The impact of tislelizumab immunotherapy on multiple primary lung cancer presenting as ground-glass nodules: preliminary results analysis from a single-arm, phase II trial. | Wu J et al. | β | 2025 | β |
| The interplay between mitochondrial DNA genotypes, female infertility, ovarian response, and mutagenesis in oocytes. | Van Der Kelen A et al. | β | 2025 | β |
| The landscape of cell lineage tracing. | Feng Y et al. | β | 2025 | β |
| The molecular cartography of malignant and benign sebaceous tumours. | Ferreira I et al. | β | 2025 | β |
| The mRNA MOXD1: Link to oxidative stress and prognostic significance in gastric cancer. | Xiao Y et al. | β | 2025 | β |
| The mutagenic forces shaping the genomes of lung cancer in neverΒ smokers. | DΓaz-Gay M et al. | β | 2025 | β |
| The mutational landscape and functional effects of noncoding ultraconserved elements in human cancers. | Bayraktar R et al. | β | 2025 | β |
| The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions. | Hayashi A et al. | β | 2025 | β |
| The origin of patient-derived cancer organoids from pathologically undiagnosed specimen in patients with pancreatobiliary cancers. | Kim B et al. | β | 2025 | β |
| The PIK3CA/AKT pathway drives therapy resistance in rhabdomyosarcoma. | Yang Q et al. | β | 2025 | β |
| The power of hybridization capture - Illustrated using an expanded gene panel on 100 post mortem samples, focusing on sudden unexplained death. | Kling D et al. | β | 2025 | β |
| The promising role of nanopore sequencing in cancer diagnostics and treatment. | Su X et al. | β | 2025 | β |
| The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. | Farooq AR et al. | β | 2025 | β |
| The Value of Integrating Hormone Receptors into Immunohistochemistry-Based Simplified Molecular Classification in Endometrial Cancer. | Zhao S et al. | β | 2025 | β |
| TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study. | Bignotti E et al. | β | 2025 | β |
| TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial. | Xia TL et al. | β | 2025 | β |
| TRIM28-dependent developmental heterogeneity determines cancer susceptibility through distinct epigenetic states. | Panzeri I et al. | β | 2025 | β |
| Tumor cell heterogeneity drives spatial organization of the intratumoral immune response. | Tanaka M et al. | β | 2025 | β |
| Uncovering minimal pathways in melanoma initiation. | Xiao H et al. | β | 2025 | β |
| UNISOM: Unified Somatic Calling and Machine Learning-based Classification Enhance the Discovery of CHIP. | Tian S et al. | β | 2025 | β |
| Unlocking the Genetic Secrets of Pancreatic Cancer: <i>KRAS</i> Allelic Imbalances in Tumor Evolution. | Liaki V et al. | β | 2025 | β |
| Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis. | Dong M et al. | β | 2025 | β |
| Utilization of primary tumor samples for cancer neoantigen discovery. | Leko V et al. | β | 2025 | β |
| Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. | DiPeri TP et al. | β | 2025 | β |
| Whole-exome sequencing for identification of specific gene mutations in an Indian cohort of triple-negative breast cancer patients. | Preeti P et al. | β | 2025 | β |
| Whole exome sequencing identifies novel somatic variants in Xinjiang Kazak esophageal squamous cell carcinoma. | Wang MB et al. | β | 2025 | β |
| Whole exome sequencing study of adamantinomatous craniopharyngioma reveals the mutational characteristics of recurrent cases. | Chen D et al. | β | 2025 | β |
| Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. | Knox JJ et al. | β | 2025 | β |
| Whole-miRNome sequencing: a panel for the targeted sequencing of all human miRNA genes. | Galka-Marciniak P et al. | β | 2025 | β |
| Zincore, an atypical coregulator, binds zinc finger transcription factors to control gene expression. | Bianchi D et al. | β | 2025 | β |
| A benchmarking study of individual somatic variant callers and voting-based ensembles for whole-exome sequencing. | Guille A et al. | β | 2024 | β |
| Accelerated Aging and Microsatellite Instability in Recessive Dystrophic Epidermolysis Bullosa-Associated Cutaneous Squamous Cell Carcinoma. | Lee CAA et al. | β | 2024 | β |
| Accelerated somatic mutation calling for whole-genome and whole-exome sequencing data from heterogenous tumor samples. | Ji S et al. | β | 2024 | β |
| A Comprehensive Study of Heterogeneous Mismatch Repair Expression in Solid Tumors Reveals Different Immunohistochemical Patterns and Distinct Genetic Mechanisms. | Wang J et al. | β | 2024 | β |
| A dendritic cell vaccine for both vaccination and neoantigen-reactive T cell preparation for cancer immunotherapy in mice. | Li Q et al. | β | 2024 | β |
| Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements. | Feinberg J et al. | β | 2024 | β |
| A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids. | Thng DKH et al. | β | 2024 | β |
| A Functional Survey of the Regulatory Landscape of Estrogen Receptor-Positive Breast Cancer Evolution. | Barozzi I et al. | β | 2024 | β |
| A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms. | Pareja F et al. | β | 2024 | β |
| Allosteric PI3KΞ± Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations. | Varkaris A et al. | β | 2024 | β |
| ALLSTAR: Inference of ReliAble CausaL RuLes between Somatic MuTAtions and CanceR Phenotypes. | Simionato D et al. | β | 2024 | β |
| Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology. | Kinnersley B et al. | β | 2024 | β |
| An analysis pipeline for understanding 6-thioguanine effects on a mouse tumour genome. | Yankilevich P et al. | β | 2024 | β |
| An atlas of epithelial cell states and plasticity in lung adenocarcinoma. | Han G et al. | β | 2024 | β |
| A Novel Affordable and Reliable Framework for Accurate Detection and Comprehensive Analysis of Somatic Mutations in Cancer. | Atzeni R et al. | β | 2024 | β |
| [Antitumor Study of Neoantigen-reactive T Cells Co-expressing IL-7 and CCL19 β©in Mouse Lung Cancer]. | Wu D et al. | β | 2024 | β |
| APC/PIK3CA mutations and Ξ²-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. | Chen M et al. | β | 2024 | β |
| AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients. | Knutson TP et al. | β | 2024 | β |
| ArCH: improving the performance of clonal hematopoiesis variant calling and interpretation. | Chan ICC et al. | β | 2024 | β |
| A regionally based precision medicine implementation initiative in North Africa:The PerMediNA consortium. | Hamdi Y et al. | β | 2024 | β |
| Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy. | Bulashevska A et al. | β | 2024 | β |
| A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa. | Neumayer G et al. | β | 2024 | β |
| A somatic genetic clock for clonal species. | Yu L et al. | β | 2024 | β |
| Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. | Ajkunic A et al. | β | 2024 | β |
| BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma. | Randall MP et al. | β | 2024 | β |
| Baseline circulating tumor DNA predicts long-term survival outcomes for patients with early breast cancer. | Zhang X et al. | β | 2024 | β |
| Beyond basics: Key mutation selection features for successful tumor-informed ctDNA detection. | Nesic M et al. | β | 2024 | β |
| Bioinformatics characterization of variants of uncertain significance in pediatric sensorineural hearing loss. | Clay S et al. | β | 2024 | β |
| Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients. | Poddubskaya E et al. | β | 2024 | β |
| Biomimetic hydrogels with mesoscale collagen architecture for patient-derived tumor organoids culture. | Wang J et al. | β | 2024 | β |
| bsgenova: an accurate, robust, and fast genotype caller for bisulfite-sequencing data. | Feng Y et al. | β | 2024 | β |
| Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion. | Pallavi R et al. | β | 2024 | β |
| Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial. | Paz-Ares L et al. | β | 2024 | β |
| CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II. | Chang Y et al. | β | 2024 | β |
| CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma. | Saba KH et al. | β | 2024 | β |
| CDX2-Suppressed Colorectal Cancers Possess Potentially Targetable Alterations in Receptor Tyrosine Kinases and Other Colorectal-Cancer-Associated Pathways. | Voutsadakis IA | β | 2024 | β |
| Cell-type-resolved mosaicism reveals clonal dynamics of the human forebrain. | Chung C et al. | β | 2024 | β |
| Cell-type-specific tumour sensitivity identified with a bromodomain targeting PROTAC in adenoid cystic carcinoma. | Rose AJ et al. | β | 2024 | β |
| Changes in chromatin accessibility and transcriptional landscape induced by HDAC inhibitors in TP53 mutated patient-derived colon cancer organoids. | Gagliano T et al. | β | 2024 | β |
| Chemoproteogenomic stratification of the missense variant cysteinome. | Desai H et al. | β | 2024 | β |
| Children born after assisted reproduction more commonly carry a mitochondrial genotype associating with low birthweight. | Mertens J et al. | β | 2024 | β |
| Chromoplexy Is a Frequent Early Clonal Event in EWSR1-Rearranged Round Cell Sarcomas That Can Be Detected Using Clinically Validated Targeted Sequencing Panels. | Dermawan JK et al. | β | 2024 | β |
| Circulating tumor DNA detection improves relapse prediction in epithelial ovarian cancer. | Zhang Y et al. | β | 2024 | β |
| Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution. | Casanova-Salas I et al. | β | 2024 | β |
| Clinical application of whole-genome sequencing of solid tumors for precision oncology. | Kim R et al. | β | 2024 | β |
| Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer. | Lin YY et al. | β | 2024 | β |
| Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer. | Boidot R et al. | β | 2024 | β |
| Clinical Interest in Exome-Based Analysis of Somatic Mutational Signatures for Non-Small Cell Lung Cancer. | Peroz M et al. | β | 2024 | β |
| Clinicopathological characteristics and genomic profiling in patients with transformed lymphoma: a monocentric retrospective study. | Zhao X et al. | β | 2024 | β |
| Clinicopathological, immunohistochemical and molecular features of acinic cell carcinoma of the breast. | Yang X et al. | β | 2024 | β |
| Clonal dominance defines metastatic dissemination in pancreatic cancer. | Ho IL et al. | β | 2024 | β |
| Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias. | Schuermans A et al. | β | 2024 | β |
| Clonal Hematopoiesis and Incident Heart Failure With Preserved Ejection Fraction. | Schuermans A et al. | β | 2024 | β |
| Clonal hematopoiesis and inflammation in the vasculature: CHIVE,Β aΒ prospective, longitudinal clonal hematopoiesis cohort and biorepository. | Shannon ML et al. | β | 2024 | β |
| Clonal hematopoiesis in people with advanced HIV and associated inflammatory syndromes. | Rocco JM et al. | β | 2024 | β |
| Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults. | Saadatagah S et al. | β | 2024 | β |
| Comparative analysis of the mutational landscape and evolutionary patterns of pancreatic ductal adenocarcinoma metastases in the liver or peritoneum. | Yao G et al. | β | 2024 | β |
| Comparing clinical and genomic features based on the tumor location in patients with resected pancreatic cancer. | Yun WG et al. | β | 2024 | β |
| Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma. | Liu F et al. | β | 2024 | β |
| Comprehensive Analysis of Microsatellite Instability in Canine Cancers: Implications for Comparative Oncology and Personalized Veterinary Medicine. | Mazzone E et al. | β | 2024 | β |
| Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center. | Kebede AM et al. | β | 2024 | β |
| Comprehensive identification of pathogenic variants in retinoblastoma by long- and short-read sequencing. | Zheng J et al. | β | 2024 | β |
| Comprehensive molecular assessment of mismatch repair deficiency in Lynch associated ovarian cancers using next generation sequencing panel. | Kim SR et al. | β | 2024 | β |
| Comprehensive molecular characterization of collecting duct carcinoma for therapeutic vulnerability. | Guan P et al. | β | 2024 | β |
| Convergent epigenetic evolution drives relapse in acute myeloid leukemia. | Nuno K et al. | β | 2024 | β |
| Converging and evolving immuno-genomic routes toward immune escape in breast cancer. | Blanco-Heredia J et al. | β | 2024 | β |
| Copy number signatures and CCNE1 amplification reveal the involvement of replication stress in high-grade endometrial tumors oncogenesis. | Marlin R et al. | β | 2024 | β |
| CRISPR/Cas9 targeting of passenger single nucleotide variants in haploinsufficient or essential genes expands cancer therapy prospects. | Kim H et al. | β | 2024 | β |
| Deconstructing Intratumoral Heterogeneity through Multiomic and Multiscale Analysis of Serial Sections. | Schupp PG et al. | β | 2024 | β |
| DEEPOMICS FFPE, a deep neural network model, identifies DNA sequencing artifacts from formalin fixed paraffin embedded tissue with high accuracy. | Heo DH et al. | β | 2024 | β |
| Deep whole-genome analysis of 494 hepatocellular carcinomas. | Chen L et al. | β | 2024 | β |
| Detecting Somatic Insertions/Deletions (Indels) Using Tumor RNA-Seq Data. | Hagiwara K et al. | β | 2024 | β |
| Detection of wildtype Merkel cell polyomavirus genomic sequence and VP1 transcription in a subset of Merkel cell carcinoma. | Kervarrec T et al. | β | 2024 | β |
| Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for gliomas. | Nakashima T et al. | β | 2024 | β |
| Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages. | Iglesia MD et al. | β | 2024 | β |
| Differential somatic coding variant landscapes between laser microdissected luminal epithelial cells from canine mammary invasive ductal solid carcinoma and comedocarcinoma. | Deckwirth V et al. | β | 2024 | β |
| Disruption of mitochondrial energy metabolism is a putative pathogenesis of Diamond-Blackfan anemia. | Xiao R et al. | β | 2024 | β |
| Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. | McIntyre CA et al. | β | 2024 | β |
| DNA damage response alterations in clear cell renal cell carcinoma: clinical, molecular, and prognostic implications. | Jing X et al. | β | 2024 | β |
| Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy. | Lin S et al. | β | 2024 | β |
| Early evolutionary branching across spatial domains predisposes to clonal replacement under chemotherapy in neuroblastoma. | Karlsson J et al. | β | 2024 | β |
| Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer. | An M et al. | β | 2024 | β |
| Effect of the mRNA decapping enzyme scavenger (DCPS) inhibitor RG3039 on glioblastoma. | Duan H et al. | β | 2024 | β |
| Empirical Bayes single nucleotide variant-calling for next-generation sequencing data. | Karimnezhad A et al. | β | 2024 | β |
| Enhancing immuno-oncology investigations through multidimensional decoding of tumor microenvironment with IOBR 2.0. | Zeng D et al. | β | 2024 | β |
| Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1. | Noguchi R et al. | β | 2024 | β |
| Establishment, characterization, and genetic profiling of patient-derived osteosarcoma cells from a patient with retinoblastoma. | Thongkumkoon P et al. | β | 2024 | β |
| Establishment of a patient-specific avatar organoid model derived from EUS-guided fine-needle biopsy for timely clinicalΒ application in pancreatic ductal adenocarcinoma (withΒ video). | Kim H et al. | β | 2024 | β |
| Evolutionary mode and timing of dissemination of high-grade serous carcinomas. | Sveen A et al. | β | 2024 | β |
| Evolutionary proteogenomic landscape from pre-invasive to invasive lung adenocarcinoma. | Zhang Y et al. | β | 2024 | β |
| Evolving copy number gains promote tumor expansion and bolster mutational diversification. | Wang Z et al. | β | 2024 | β |
| Exploring the Role of Non-synonymous and Deleterious Variants Identified in Colorectal Cancer: A Multi-dimensional Computational Scrutiny of Exomes. | Karunakaran C et al. | β | 2024 | β |
| Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies. | Weiss S et al. | β | 2024 | β |
| Extrachromosomal circular DNA orchestrates genome heterogeneity in urothelial bladder carcinoma. | Lv W et al. | β | 2024 | β |
| Familial gigantiform cementoma with recurrent ANO5 p.Cys356Tyr mutations: Clinicopathological and genetic study with literature review. | Zhou Z et al. | β | 2024 | β |
| FLI1 is associated with regulation of DNA methylation and megakaryocytic differentiation in FPDMM caused by a RUNX1 transactivation domain mutation. | Tanaka Y et al. | β | 2024 | β |
| Folate intake and colorectal cancer risk according to genetic subtypes defined by targeted tumor sequencing. | Aglago EK et al. | β | 2024 | β |
| Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments. | Krull JE et al. | β | 2024 | β |
| From Omics to Multi-Omics: A Review of Advantages and Tradeoffs. | Hayes CN et al. | β | 2024 | β |
| Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression. | Chen Z et al. | β | 2024 | β |
| Gene features of tumor-specific T cells relevant to immunotherapy, targeted therapy and chemotherapy in lung cancer. | Luo Z et al. | β | 2024 | β |
| Genetic and epigenetic alterations in precursor lesions of endometrial endometrioid carcinoma. | Gotoh O et al. | β | 2024 | β |
| Genetic variation across and within individuals. | Yu Z et al. | β | 2024 | β |
| Genomes and epigenomes of matched normal and tumor breast tissue reveal diverse evolutionary trajectories and tumor-host interactions. | Zhu B et al. | β | 2024 | β |
| Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1. | Parker HG et al. | β | 2024 | β |
| Genome-Wide Characterization of Somatic Mutation Patterns in Cloned Dogs Reveals Implications for Neuronal Function, Tumorigenesis, and Aging. | Woo SW et al. | β | 2024 | β |
| Genomic alterations in oral multiple primary cancers. | Zhou X et al. | β | 2024 | β |
| Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations. | Dopeso H et al. | β | 2024 | β |
| Genomic and immune heterogeneity of multiple synchronous lung adenocarcinoma at different developmental stages. | Zhao Y et al. | β | 2024 | β |
| Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer. | Wang X et al. | β | 2024 | β |
| Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer. | Zhu X et al. | β | 2024 | β |
| Genomic and transcriptomic landscape of human gastrointestinal stromal tumors. | Xie F et al. | β | 2024 | β |
| Genomic characteristics and evolution of Multicentric Esophageal and gastric Cardiac Cancer. | Liu X et al. | β | 2024 | β |
| Genomic characteristics and immune landscape of super multiple primary lung cancer. | Yang Z et al. | β | 2024 | β |
| Genomic characterization and risk stratification of esophageal squamous dysplasia. | Min Q et al. | β | 2024 | β |
| Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. | Zhao Y et al. | β | 2024 | β |
| Genomic Engineering of Oral Keratinocytes to Establish In Vitro Oral Potentially Malignant Disease Models as a Platform for Treatment Investigation. | Wils LJ et al. | β | 2024 | β |
| Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma. | Chen Z et al. | β | 2024 | β |
| Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma. | Tarantino G et al. | β | 2024 | β |
| Genomic heterogeneity of multiple synchronous lung cancers in Chinese population. | Zhao L et al. | β | 2024 | β |
| Genomic Mosaicism of the Brain: Origin, Impact, and Utility. | Graham JH et al. | β | 2024 | β |
| Genomic Profiling and Immune Phenotyping of Neuroendocrine Bladder Cancer. | Zang J et al. | β | 2024 | β |
| Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression. | FlΓ©chon L et al. | β | 2024 | β |
| Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma. | Kazandjian D et al. | β | 2024 | β |
| Genomic, transcriptomic, and T cell receptor profiling in stratifying response to first-line chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma. | Zhang X et al. | β | 2024 | β |
| Germline functional variants contribute to somatic mutation and outcomes in neuroblastoma. | Seo ES et al. | β | 2024 | β |
| Germline susceptibility from broad genomic profiling of pediatric brain cancers. | Mardis ER et al. | β | 2024 | β |
| GNA14 and GNAQ somatic mutations cause spinal and intracranial extra-axial cavernous hemangiomas. | Ren J et al. | β | 2024 | β |
| Grading Cytologic Epithelial Atypia in Pancreatic Mucinous Cysts Predicts Patient Survival: Correlation With Histologic, Molecular, and Clinical Follow-Up. | Zhang ML et al. | β | 2024 | β |
| Hallmarks of a genomically distinct subclass of head and neck cancer. | Muijlwijk T et al. | β | 2024 | β |
| High performance TadA-8e derived cytosine and dual base editors with undetectable off-target effects in plants. | Fan T et al. | β | 2024 | β |
| Histologic and Genomic Analysis of Conjunctival SCC in African and American Cohorts Reveal UV Light and HPV Signatures and High Tumor Mutation Burden. | Gleber-Netto FO et al. | β | 2024 | β |
| Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119. | KΓΆhnke T et al. | β | 2024 | β |
| Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study. | Wang R et al. | β | 2024 | β |
| Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data. | Nagarajan N et al. | β | 2024 | β |
| Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. | Bruedigam C et al. | β | 2024 | β |
| Immune checkpoint markers and tumour mutation burden in Wilms tumour: a study of 59 cases. | Mattis AJ et al. | β | 2024 | β |
| Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. | Nabet BY et al. | β | 2024 | β |
| Immune-tumor interaction dictates spatially directed evolution of esophageal squamous cell carcinoma. | Zhou Y et al. | β | 2024 | β |
| Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment. | Levine AB et al. | β | 2024 | β |
| Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease. | Marchetti A et al. | β | 2024 | β |
| Impact of cytotoxic therapy on clonal hematopoiesis and myeloid neoplasms in breast cancer patients. | Kim H et al. | β | 2024 | β |
| Impaired neutrophil-mediated cell death drives Ewing's Sarcoma in the background of Down syndrome. | Peirone S et al. | β | 2024 | β |
| Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of <i>Arid1a</i> mutations. | D'Ambrosio A et al. | β | 2024 | β |
| Inherited BRCA1 and RNF43 pathogenic variants in a familial colorectal cancer type X family. | Chan JM et al. | β | 2024 | β |
| In silico neoantigen screening and HLA multimer-based validation identify immunogenic neopeptide in multifocal lung adenocarcinoma. | Wang X et al. | β | 2024 | β |
| Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer. | Zhao SG et al. | β | 2024 | β |
| Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target. | Duan H et al. | β | 2024 | β |
| Integrated approach to generate artificial samples with low tumor fraction for somatic variant calling benchmarking. | Sergi A et al. | β | 2024 | β |
| Integrated drug response prediction models pinpoint repurposed drugs with effectiveness against rhabdomyosarcoma. | Baek B et al. | β | 2024 | β |
| Integrated proteogenomic characterization of glioblastoma evolution. | Kim KH et al. | β | 2024 | β |
| Integrative identification of non-coding regulatory regions driving metastatic prostate cancer. | Woo BJ et al. | β | 2024 | β |
| Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma. | Liu H et al. | β | 2024 | β |
| Integrative multi-omics characterization of hepatocellular carcinoma in Hispanic patients. | Das D et al. | β | 2024 | β |
| Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer. | Pan J et al. | β | 2024 | β |
| Invasive Assessment of Coronary Artery Disease in Clonal Hematopoiesis of Indeterminate Potential. | Heimlich JB et al. | β | 2024 | β |
| Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy. | Ahn B et al. | β | 2024 | β |
| Investigating the Use of Circulating Tumor DNA for Sarcoma Management. | Darville-O'Quinn P et al. | β | 2024 | β |
| Large and Extensive Multilocular Peritoneal Inclusion Cysts Lack Genomic Alterations and Follow an Indolent Clinical Course Despite Rare Recurrences. | Devins KM et al. | β | 2024 | β |
| Leveraging new methods for comprehensive characterization of mitochondrial DNA in esophageal squamous cell carcinoma. | Zhuang X et al. | β | 2024 | β |
| Liquid Biopsy Profiling with Multiple Tests in Patients with Metastatic Breast Cancer. | Higa N et al. | β | 2024 | β |
| Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer. | Wang K et al. | β | 2024 | β |
| Low-level brain somatic mutations in exonic regions are collectively implicated in autism with germline mutations in autism risk genes. | Kim IB et al. | β | 2024 | β |
| <i>Hydra</i> has mammal-like mutation rates facilitating fast adaptation despite its nonaging phenotype. | Sahm A et al. | β | 2024 | β |
| <i>RMND1</i> Mutation Case Report and Literature Review. | Bayrak H et al. | β | 2024 | β |
| Malignant features of minipig melanomas prior to spontaneous regression. | DΓ©bare H et al. | β | 2024 | β |
| Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer. | Di Chiaro P et al. | β | 2024 | β |
| Mechanisms of action and resistance in histone methylation-targeted therapy. | Yamagishi M et al. | β | 2024 | β |
| Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. | Araujo HA et al. | β | 2024 | β |
| Metabolic stress in space: ROS-induced mutations in mice hint at a new path to cancer. | Stolc V et al. | β | 2024 | β |
| Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort. | Camarena ME et al. | β | 2024 | β |
| Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiation. | JonchΓ¨re V et al. | β | 2024 | β |
| Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms. | Xu Y et al. | β | 2024 | β |
| Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms. | Hong YS et al. | β | 2024 | β |
| Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. | Hobor S et al. | β | 2024 | β |
| Molecular characterization of gliomas and glioneuronal tumors amid Noonan syndrome: cancer predisposition examined. | Shatara M et al. | β | 2024 | β |
| Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas. | Zhang J et al. | β | 2024 | β |
| Molecular landscape and multi-omic measurements of heterogeneity in fetal adenocarcinoma of the lung. | Sun L et al. | β | 2024 | β |
| Molecular pathology as basis for timely cancer diagnosis and therapy. | Mackinnon AC et al. | β | 2024 | β |
| Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma. | Chao A et al. | β | 2024 | β |
| Multilayered epigenetic control of persistent and stage-specific imprinted genes in rice endosperm. | Tonosaki K et al. | β | 2024 | β |
| Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck. | Sanz-Garcia E et al. | β | 2024 | β |
| Multimodal Integrative Genomics and Pathology Analyses in Neoadjuvant Nivolumab Treatment for Intermediate and Locally Advanced Hepatocellular Carcinoma. | Cheung TT et al. | β | 2024 | β |
| Multi-omic profiling reveals associations between the gut microbiome, host genome and transcriptome in patients with colorectal cancer. | Zou S et al. | β | 2024 | β |
| Multi-omics analysis reveals critical metabolic regulators in bladder cancer. | Wei C et al. | β | 2024 | β |
| Multi-OMICS approaches in cancer biology: New era in cancer therapy. | Chakraborty S et al. | β | 2024 | β |
| Multi-omics approach for identifying CNV-associated lncRNA signatures with prognostic value in prostate cancer. | Tyagi N et al. | β | 2024 | β |
| Multiplex digital profiling of DNA methylation heterogeneity for sensitive and cost-effective cancer detection in low-volume liquid biopsies. | Zhao Y et al. | β | 2024 | β |
| Multi-regional sequencing reveals the genetic and immune heterogeneity of non-cancerous tissues in gastric cancer. | Zhou Y et al. | β | 2024 | β |
| Multiregion exome sequencing indicates a monoclonal origin of esophageal spindle-cell squamous cell carcinoma. | Wang Y et al. | β | 2024 | β |
| Multi-scale signaling and tumor evolution in high-grade gliomas. | Liu J et al. | β | 2024 | β |
| Mutational landscape of head and neck cancer and cervical cancer in Chinese and Western population. | Li Q et al. | β | 2024 | β |
| Mutational landscape of inflammatory breast cancer. | Bertucci F et al. | β | 2024 | β |
| Mutational profile evaluates metastatic capacity of Chinese colorectal cancer patients, revealed by whole-exome sequencing. | Yang Y et al. | β | 2024 | β |
| Mutational signatures in 175 Chinese gastric cancer patients. | Liu F et al. | β | 2024 | β |
| Mutation detection in saliva from oral cancer patients. | Ahmed AA et al. | β | 2024 | β |
| Mutation in the mitochondrial chaperone TRAP1 leads to autism with more severe symptoms in males. | Rydzanicz M et al. | β | 2024 | β |
| Mutation of SIVA, a candidate metastasis gene identified from clonally related bilateral breast cancers, promotes breast cancer cell spread in vitro and in vivo. | Vermehren-Schmaedick A et al. | β | 2024 | β |
| Mutations of ARID1B, PIK3C2B, KMT2B, and FAT1 genes influence clinical outcome in newly diagnosed myeloma. | Morawska M et al. | β | 2024 | β |
| Neoantigen identification: Technological advances and challenges. | Pu T et al. | β | 2024 | β |
| Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived TΒ cells exhibiting the full differentiation spectrum. | Ingels J et al. | β | 2024 | β |
| Next generation sequencing reveals the mutation landscape of Chinese MDS patients and the association between mutations and AML transformations. | Liu Y et al. | β | 2024 | β |
| Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways. | Skadborg SK et al. | β | 2024 | β |
| No evidence of immunosurveillance in mutation-hotspot driven clonal haematopoiesis | Walkowiak B et al. | β | 2024 | β |
| Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced Mutations. | Huang CY et al. | β | 2024 | β |
| Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach. | Schott CR et al. | β | 2024 | β |
| Osteosarcomas With Few Chromosomal Alterations or Adult Onset Are Genetically Heterogeneous. | Difilippo V et al. | β | 2024 | β |
| p53-dependent crosstalk between DNA replication integrity and redox metabolism mediated through a NRF2-PARP1 axis. | Elfar GA et al. | β | 2024 | β |
| Papillary Hemangioma Harbors Somatic GNA11 and GNAQ Mutations. | Gestrich CK et al. | β | 2024 | β |
| Parameter estimation from single patient, single time-point sequencing data of recurrent tumors. | Leder K et al. | β | 2024 | β |
| Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis. | Mochizuki A et al. | β | 2024 | β |
| Personalized oncology in pheochromocytomas and paragangliomas: integrating genetic analysis with machine learning. | Abida et al. | β | 2024 | β |
| Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics. | Zhang J et al. | β | 2024 | β |
| Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer. | Yang H et al. | β | 2024 | β |
| Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. | Piha-Paul SA et al. | β | 2024 | β |
| PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL. | Lahera A et al. | β | 2024 | β |
| Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic Features. | Wijetunga NA et al. | β | 2024 | β |
| Post-therapy emergence of an NBN reversion mutation in a patient with pancreatic acinar cell carcinoma. | Pelster MS et al. | β | 2024 | β |
| Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure. | Yuan X et al. | β | 2024 | β |
| Prediction of the 3D cancer genome from whole-genome sequencing using InfoHiC. | Lee Y et al. | β | 2024 | β |
| Prognostic genome and transcriptome signatures in colorectal cancers. | Nunes L et al. | β | 2024 | β |
| Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance. | Yoon KA et al. | β | 2024 | β |
| Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer. | Yao P et al. | β | 2024 | β |
| Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. | Liu Q et al. | β | 2024 | β |
| Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets. | Xu G et al. | β | 2024 | β |
| Race-specific coregulatory and transcriptomic profiles associated with DNA methylation and androgen receptor in prostate cancer. | Ramakrishnan S et al. | β | 2024 | β |
| Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. | Choudhury AD et al. | β | 2024 | β |
| RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. | Nokin MJ et al. | β | 2024 | β |
| Reconstructing oral cavity tumor evolution through brush biopsy. | John E et al. | β | 2024 | β |
| Reconstructing phylogenetic trees from genome-wide somatic mutations in clonal samples. | Coorens THH et al. | β | 2024 | β |
| Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies. | Aparicio B et al. | β | 2024 | β |
| Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models. | Hynds RE et al. | β | 2024 | β |
| Resolving intra-repeat variation in medically relevant VNTRs from short-read sequencing data using the cardiovascular risk gene LPA as a model. | Di Maio S et al. | β | 2024 | β |
| Revisiting the performance of cyst fluid carcinoembryonic antigen as a diagnostic marker for pancreatic mucinous cysts: a comprehensive 20-year institutional review. | Kwan MC et al. | β | 2024 | β |
| RNA expression of 6 genes from metastatic mucosal gastric cancer serves as the global prognostic marker for gastric cancer with functional validation. | Suh YS et al. | β | 2024 | β |
| Scrambling the genome in cancer: causes and consequences of complex chromosome rearrangements. | Krupina K et al. | β | 2024 | β |
| Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging. | Jakobsen NA et al. | β | 2024 | β |
| Single nucleotide variants in nuclear pore complex disassembly pathway associated with poor survival in osteosarcoma. | Jacobs JE et al. | β | 2024 | β |
| Somatic <i>GNAQ</i>, <i>CTNNB1</i>, and <i>CACNA1C</i> Mutations in Cat Aldosterone-Secreting Tumors. | Watson A et al. | β | 2024 | β |
| Somatic mutations in autoinflammatory and autoimmune disease. | Torreggiani S et al. | β | 2024 | β |
| Somatic mutations of esophageal adenocarcinoma: a comparison between Black and White patients. | Lim H et al. | β | 2024 | β |
| Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases. | Zhao JJ et al. | β | 2024 | β |
| Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer. | Beckabir W et al. | β | 2024 | β |
| SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis. | Yavas A et al. | β | 2024 | β |
| Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy. | Liu XD et al. | β | 2024 | β |
| TBX15 and SDHB expression changes in colorectal cancer serve as potential prognostic biomarkers. | Golozar M et al. | β | 2024 | β |
| The Association between Mutational Signatures and Clinical Outcomes among Patients with Early-Onset Breast Cancer. | Basmadjian RB et al. | β | 2024 | β |
| The colibactin-producing <i>Escherichia coli</i> alters the tumor microenvironment to immunosuppressive lipid overload facilitating colorectal cancer progression and chemoresistance. | de Oliveira Alves N et al. | β | 2024 | β |
| The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation. | Backman S et al. | β | 2024 | β |
| The genetic evolution of acral melanoma. | Wang M et al. | β | 2024 | β |
| The genomic and evolutionary landscapes of anaplastic thyroid carcinoma. | Zeng PYF et al. | β | 2024 | β |
| The genomic landscape of 2,023 colorectal cancers. | Cornish AJ et al. | β | 2024 | β |
| The identification and analysis of meristematic mutations within the apple tree that developed the RubyMac sport mutation. | Sun H et al. | β | 2024 | β |
| The impact of age and number of mutations on the size of clonal hematopoiesis. | Wang K et al. | β | 2024 | β |
| The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma. | Jiang G et al. | β | 2024 | β |
| The K9 lymphoma assay allows a genetic subgrouping of canine lymphomas with improved risk classification. | Fanelli A et al. | β | 2024 | β |
| The potential role of next-generation sequencing in identifying <i>MET</i> amplification and disclosing resistance mechanisms in NSCLC patients with osimertinib resistance. | Xiao X et al. | β | 2024 | β |
| The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. | Caswell DR et al. | β | 2024 | β |
| Three molecular subtypes and a five-gene signature for hepatocellular carcinoma based on m7G-related classification. | Yue Y et al. | β | 2024 | β |
| Topographic analysis of pancreatic cancer by TMA and digital spatial profiling reveals biological complexity with potential therapeutic implications. | Bingham V et al. | β | 2024 | β |
| Transcriptome Deconvolution Reveals Absence of Cancer Cell Expression Signature in Immune Checkpoint Blockade Response. | Guo YA et al. | β | 2024 | β |
| Transformers meets neoantigen detection: a systematic literature review. | Machaca V et al. | β | 2024 | β |
| Translational bioinformatics approach to combat cardiovascular disease and cancers. | Shahjahan et al. | β | 2024 | β |
| Treatment Monitoring of a Patient with Synchronous Metastatic Angiosarcoma and Breast Cancer Using ctDNA. | Vannas C et al. | β | 2024 | β |
| Treatment resistance to melanoma therapeutics on a single cell level. | Yao L et al. | β | 2024 | β |
| Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer. | Fernandez-Mateos J et al. | β | 2024 | β |
| Tumor microenvironment assessment-based signatures for predicting response to immunotherapy in non-small cell lung cancer. | Wu J et al. | β | 2024 | β |
| Tumor mutation burden and <i>FAT3</i> mutation influence long-term survival in surgically resected small cell lung cancer. | Qian X et al. | β | 2024 | β |
| Tumor Neoepitope-Based Vaccines: A Scoping Review on Current Predictive Computational Strategies. | Rocha LGDN et al. | β | 2024 | β |
| Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in Hepatocellular Carcinoma. | Liu X et al. | β | 2024 | β |
| Tumour evolution and microenvironment interactions in 2D and 3D space. | Mo CK et al. | β | 2024 | β |
| Unraveling the role of hepatitis B virus DNA integration in B-cell lymphomagenesis. | Cheng CL et al. | β | 2024 | β |
| Unravelling the Genetic Landscape of Hemiplegic Migraine: Exploring Innovative Strategies and Emerging Approaches. | Alfayyadh MM et al. | β | 2024 | β |
| Upstream open reading frames: new players in the landscape of cancer gene regulation. | Dasgupta A et al. | β | 2024 | β |
| Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations. | Wiedmeier-Nutor JE et al. | β | 2024 | β |
| Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy. | Bertucci F et al. | β | 2024 | β |
| Whole-Exome Sequencing and Experimental Validation Unveil the Roles of TMEM229A Q200del Mutation in Lung Adenocarcinoma. | Liang YX et al. | β | 2024 | β |
| Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei. | Lin YL et al. | β | 2024 | β |
| Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study. | OelschlΓ€ger L et al. | β | 2024 | β |
| Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways. | White JA et al. | β | 2024 | β |
| Whole exome sequencing reveals diverse genomic relatedness between paired concurrent endometrial and ovarian carcinomas. | Southworth E et al. | β | 2024 | β |
| Whole-exome sequencing reveals genomic landscape of intrahepatic cholangiocarcinoma and identifies SAV1 as a potential driver. | Zhou ZJ et al. | β | 2024 | β |
| Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma. | Nokchan N et al. | β | 2024 | β |
| Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models. | Wu CC et al. | β | 2024 | β |
| Whole genome sequencing of HER2-positive metastatic extramammary Paget's disease: a case report. | Lim BY et al. | β | 2024 | β |
| Whole-Genome Sequencing Reveals Rare Off-Target Mutations in <i>MC1R</i>-Edited Pigs Generated by Using CRISPR-Cas9 and Somatic Cell Nuclear Transfer. | Li Z et al. | β | 2024 | β |
| Widespread alteration of protein autoinhibition in human cancers. | Holguin-Cruz JA et al. | β | 2024 | β |
| Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis. | Weinstock JS et al. | β | 2023 | β |
| ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization. | Lyon A et al. | β | 2023 | β |
| Absence of Lugol staining indicates initiation of esophageal squamous cell carcinoma: A combined genomic and epidemiologic study. | Liu Z et al. | β | 2023 | β |
| A Comprehensive Analysis of Cutaneous Melanoma Patients in Greece Based on Multi-Omic Data. | Kontogianni G et al. | β | 2023 | β |
| Acquired DNA damage repairs deficiency-driven immune evolution and involved immune factors of local versus distant metastases in non-small cell lung cancer. | Tang WF et al. | β | 2023 | β |
| Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype. | Hiltbrunner S et al. | β | 2023 | β |
| A critical spotlight on the paradigms of FFPE-DNA sequencing. | Steiert TA et al. | β | 2023 | β |
| ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA. | Huebner A et al. | β | 2023 | β |
| Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial. | Guo C et al. | β | 2023 | β |
| Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches. | Huang R et al. | β | 2023 | β |
| Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome. | Bolivar AM et al. | β | 2023 | β |
| Advances of mRNA vaccine in tumor: a maze of opportunities and challenges. | Yuan Y et al. | β | 2023 | β |
| Age at Menopause, Leukocyte Telomere Length, and Coronary Artery Disease in Postmenopausal Women. | Schuermans A et al. | β | 2023 | β |
| Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by <i>TET2</i>, <i>TP53</i>, and <i>CBL</i> mutations. | Dawoud AAZ et al. | β | 2023 | β |
| A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options. | Sun L et al. | β | 2023 | β |
| AIVariant: a deep learning-based somatic variant detector for highly contaminated tumor samples. | Jeon H et al. | β | 2023 | β |
| A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification. | Choi SW et al. | β | 2023 | β |
| An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress. | Igarashi T et al. | β | 2023 | β |
| Angioimmunoblastic T-cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell-free DNA profiling. | Zhang C et al. | β | 2023 | β |
| An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. | Chen YX et al. | β | 2023 | β |
| An Integrative Analysis of Nasopharyngeal Carcinoma Genomes Unraveled Unique Processes Driving a Viral-Positive Cancer. | Liu X et al. | β | 2023 | β |
| An integrative approach for exploring the nature of fibroepithelial neoplasms. | Yun J et al. | β | 2023 | β |
| A novel subclonal rearrangement of the STRN3::PDGFRB gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects. | Wang Z et al. | β | 2023 | β |
| A Phase Ib Trial of AVID200, a TGFΞ² 1/3 Trap, in Patients with Myelofibrosis. | Mascarenhas J et al. | β | 2023 | β |
| A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy. | Gambaro K et al. | β | 2023 | β |
| A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. | Piperno-Neumann S et al. | β | 2023 | β |
| APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis. | Long X et al. | β | 2023 | β |
| A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets. | Vlasschaert C et al. | β | 2023 | β |
| A proteogenomics data-driven knowledge base of human cancer. | Liao Y et al. | β | 2023 | β |
| Artificial Intelligence-Driven Morphology-Based Enrichment of Malignant Cells from Body Fluid. | Mavropoulos A et al. | β | 2023 | β |
| Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction. | Li T et al. | β | 2023 | β |
| Association between vascular ultrasound features and DNA sequencing in breast cancer: a preliminary study. | Han MR et al. | β | 2023 | β |
| Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility. | Talwar JV et al. | β | 2023 | β |
| Barcoded multiple displacement amplification for high coverage sequencing in spatial genomics. | Kim J et al. | β | 2023 | β |
| Birth Weight Is Associated With Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Outcomes in Adulthood. | Schuermans A et al. | β | 2023 | β |
| Bladder cancer organoids as a functional system to model different disease stages and therapy response. | Minoli M et al. | β | 2023 | β |
| BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors. | Fu Y et al. | β | 2023 | β |
| Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment. | Huang M et al. | β | 2023 | β |
| CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden. | van den Bulk J et al. | β | 2023 | β |
| CD103<sup>+</sup> regulatory T cells underlie resistance to radio-immunotherapy and impair CD8<sup>+</sup> T cell activation in glioblastoma. | van Hooren L et al. | β | 2023 | β |
| cfSNV: a software tool for the sensitive detection of somatic mutations from cell-free DNA. | Li S et al. | β | 2023 | β |
| Characterization of Cell-Free DNA Size Distribution in Osteosarcoma Patients. | Udomruk S et al. | β | 2023 | β |
| Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential. | NamlΓΈs HM et al. | β | 2023 | β |
| Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients. | Taylor K et al. | β | 2023 | β |
| Clear cell renal cell carcinoma molecular variations in non-Hispanic White and Hispanic patients. | Batai K et al. | β | 2023 | β |
| Client Applications and Server-Side Docker for Management of RNASeq and/or VariantSeq Workflows and Pipelines of the GPRO Suite. | Hafez AI et al. | β | 2023 | β |
| Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing. | He Y et al. | β | 2023 | β |
| Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma. | Valero C et al. | β | 2023 | β |
| Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma. | Mouhieddine TH et al. | β | 2023 | β |
| Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patients. | Kim S et al. | β | 2023 | β |
| Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity? | Yu J et al. | β | 2023 | β |
| Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men. | Wang A et al. | β | 2023 | β |
| Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. | Fairchild L et al. | β | 2023 | β |
| Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease. | Gumuser ED et al. | β | 2023 | β |
| Clonally Selected Lines After CRISPR-Cas Editing Are Not Isogenic. | Panda A et al. | β | 2023 | β |
| Co-evolution of <i>AR</i> gene copy number and structural complexity in endocrine therapy resistant prostate cancer. | Zivanovic A et al. | β | 2023 | β |
| Colorectal Cancer Organoid-Stroma Biobank Allows Subtype-Specific Assessment of Individualized Therapy Responses. | Farin HF et al. | β | 2023 | β |
| Combined PD-1, BRAF and MEK inhibition in BRAF<sup>V600E</sup> colorectal cancer: a phase 2 trial. | Tian J et al. | β | 2023 | β |
| Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. | Wu Y et al. | β | 2023 | β |
| Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation. | Kim SJ et al. | β | 2023 | β |
| Complete loss of <i>TP53</i> and <i>RB1</i> is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma. | Beird HC et al. | β | 2023 | β |
| Comprehension of rectosigmoid junction cancer molecular features by comparison to the rectum or sigmoid colon cancer. | Zhu Q et al. | β | 2023 | β |
| Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. | Thatikonda V et al. | β | 2023 | β |
| Comprehensive and realistic simulation of tumour genomic sequencing data. | O'Sullivan B et al. | β | 2023 | β |
| Comprehensive benchmarking and guidelines of mosaic variant calling strategies. | Ha YJ et al. | β | 2023 | β |
| Comprehensive proteogenomic characterization of early duodenal cancer reveals the carcinogenesis tracks of different subtypes. | Li L et al. | β | 2023 | β |
| Concordance between whole exome sequencing of circulating tumor DNA and tumor tissue. | Leenanitikul J et al. | β | 2023 | β |
| ConDoR: tumor phylogeny inference with a copy-number constrained mutation loss model. | Sashittal P et al. | β | 2023 | β |
| Control-independent mosaic single nucleotide variant detection with DeepMosaic. | Yang X et al. | β | 2023 | β |
| COVID-19 relapse associated with SARS-CoV-2 evasion from CD4<sup>+</sup> T-cell recognition in an agammaglobulinemia patient. | Morita R et al. | β | 2023 | β |
| Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer. | Wong K et al. | β | 2023 | β |
| Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery. | Zhang B et al. | β | 2023 | β |
| Cylindroma of the breast with CYLD gene mutation: a case report and review of the literature. | Escher-Michlig V et al. | β | 2023 | β |
| Deep exome sequencing identifies enrichment of deleterious mosaic variants in neurodevelopmental disorder genes and mitochondrial tRNA regions in bipolar disorder. | Nishioka M et al. | β | 2023 | β |
| Deep sequencing reveals recurrent somatic mutations and distinct molecular subgroups in gastric cancer in Mizo population, North East India. | Chakraborty P et al. | β | 2023 | β |
| Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel. | Glodzik D et al. | β | 2023 | β |
| Diagnosis of Ovarian Carcinoma Homologous Recombination DNA Repair Deficiency From Targeted Gene Capture Oncology Assays. | Krumm N et al. | β | 2023 | β |
| Distinct aneuploid evolution of astrocytoma and glioblastoma during recurrence. | Zhang J et al. | β | 2023 | β |
| Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma. | Barnell EK et al. | β | 2023 | β |
| Distinct genomic landscapes in radiation-associated angiosarcoma compared with other radiation-associated sarcoma histologies. | Dermawan JK et al. | β | 2023 | β |
| Donor-Derived Follicular Lymphoma After Kidney Transplantation: A Case Report. | Singhal K et al. | β | 2023 | β |
| Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer. | Zeng L et al. | β | 2023 | β |
| Efficient exon skipping by base-editor-mediated abrogation of exonic splicing enhancers. | Qiu H et al. | β | 2023 | β |
| Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation. | Wils LJ et al. | β | 2023 | β |
| Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer. | Freshour SL et al. | β | 2023 | β |
| Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. | Ptashkin RN et al. | β | 2023 | β |
| Enhanced mitochondrial genome analysis: bioinformatic and long-read sequencing advances and their diagnostic implications. | Macken WL et al. | β | 2023 | β |
| Enhancing oral squamous cell carcinoma prediction: the prognostic power of the worst pattern of invasion and the limited impact of molecular resection margins. | HurnΓk P et al. | β | 2023 | β |
| Epigenetic regulation during cancer transitions across 11 tumour types. | Terekhanova NV et al. | β | 2023 | β |
| Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens. | Yamanaka S et al. | β | 2023 | β |
| Evidence for etiologic field changes in tongue distant from tumor in patients with squamous cell carcinoma of the oral tongue. | Gu X et al. | β | 2023 | β |
| Evolution of structural rearrangements in prostate cancer intracranial metastases. | Khani F et al. | β | 2023 | β |
| Evolution of synchronous female bilateral breast cancers and response to treatment. | Hamy AS et al. | β | 2023 | β |
| Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations. | Mandelker D et al. | β | 2023 | β |
| Exposure to microbial products followed by loss of Tet2 promotes myelodysplastic syndrome via remodeling HSCs. | Yokomizo-Nakano T et al. | β | 2023 | β |
| Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance. | Cotton JL et al. | β | 2023 | β |
| First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial. | Thibaudin M et al. | β | 2023 | β |
| Gene signatures associated with prognosis and chemotherapy resistance in glioblastoma treated with temozolomide. | Carter T et al. | β | 2023 | β |
| Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms. | Chovanec J et al. | β | 2023 | β |
| Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival. | Kotnik EN et al. | β | 2023 | β |
| Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples. | Khalsa JK et al. | β | 2023 | β |
| Genetic heterogeneity and enrichment of variants in DNA-repair genes in ameloblastoma. | Awotoye W et al. | β | 2023 | β |
| Genetic landscape and PD-L1 expression in Epstein-Barr virus-associated gastric cancer according to the histological pattern. | Park JH et al. | β | 2023 | β |
| Genetic modification of inflammation- and clonal hematopoiesis-associated cardiovascular risk. | Yu Z et al. | β | 2023 | β |
| Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis. | Tian H et al. | β | 2023 | β |
| Genome- and transcriptome-wide off-target analyses of a high-efficiency adenine base editor in tomato. | Sretenovic S et al. | β | 2023 | β |
| Genomic alterations dissection revealed <i>MUC4</i> mutation as a potential driver in lung adenocarcinoma local recurrence. | Yuan C et al. | β | 2023 | β |
| Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients. | Lang B et al. | β | 2023 | β |
| Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma. | Calsina B et al. | β | 2023 | β |
| Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer. | Malagoli Tagliazucchi G et al. | β | 2023 | β |
| Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. | Ravi A et al. | β | 2023 | β |
| Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non-Small Cell Lung Cancer. | Liao R et al. | β | 2023 | β |
| Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer. | Kim JY et al. | β | 2023 | β |
| Genomic data resources of the Brain Somatic Mosaicism Network for neuropsychiatric diseases. | Garrison MA et al. | β | 2023 | β |
| Genomic features and its potential implication in bone oligometastatic NSCLC. | Liao R et al. | β | 2023 | β |
| Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer. | Paracchini L et al. | β | 2023 | β |
| Genomic landscape of TP53-mutated myeloid malignancies. | Abel HJ et al. | β | 2023 | β |
| Genomic profile of two Brazilian choroid plexus tumors by whole-exome sequencing. | Garcia FAO et al. | β | 2023 | β |
| Genomic profiling and immune landscape of olfactory neuroblastoma in China. | Yang Y et al. | β | 2023 | β |
| Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype. | Fitzpatrick A et al. | β | 2023 | β |
| Genomic profiling of a metastatic anaplastic melanocytic neuroectodermal tumor arising from a mature thymic teratoma as part of a mediastinal germ cell tumor. | Mayeur S et al. | β | 2023 | β |
| Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer. | He F et al. | β | 2023 | β |
| Genomics of <i>ERBB2</i>-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab. | Lipsyc-Sharf M et al. | β | 2023 | β |
| Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer. | Kamran SC et al. | β | 2023 | β |
| Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations. | Liu Y et al. | β | 2023 | β |
| GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells. | Turkalj S et al. | β | 2023 | β |
| Heterogeneity and potential therapeutic insights for triple-negative breast cancer based on metabolic-associated molecular subtypes and genomic mutations. | Li L et al. | β | 2023 | β |
| Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. | Li Y et al. | β | 2023 | β |
| How low can you go?: Methodologic considerations in clonal hematopoiesis variant calling. | Beeler JS et al. | β | 2023 | β |
| Human 8-cell embryos enable efficient induction of disease-preventive mutations without off-target effect by cytosine base editor. | Wei Y et al. | β | 2023 | β |
| Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma. | Marino-Enriquez A et al. | β | 2023 | β |
| <i>CHEK2</i> Alterations in Pediatric Malignancy: A Single-Institution Experience. | Abdelghani E et al. | β | 2023 | β |
| Identification and targeting of cancer-associated fibroblast signature genes for prognosis and therapy in Cutaneous melanoma. | Zhang G et al. | β | 2023 | β |
| Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire. | Millar DG et al. | β | 2023 | β |
| Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma. | Abril-Fornaguera J et al. | β | 2023 | β |
| Identification of MKI67, TPR , and TCHH Mutations as Prognostic Biomarkers for Patients With Defective Mismatch Repair Colon Cancer Stage II/III. | Lv J et al. | β | 2023 | β |
| Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma. | Liu E et al. | β | 2023 | β |
| Identifying the Common Cell-Free DNA Biomarkers across Seven Major Cancer Types. | Luo M et al. | β | 2023 | β |
| IDH-negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site-A diagnostic pitfall. | Sekita T et al. | β | 2023 | β |
| Immune-active tumor-adjacent tissues are associated with favorable prognosis in stage I lung squamous cell carcinoma. | Ying L et al. | β | 2023 | β |
| Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice. | Isidro-HernΓ‘ndez M et al. | β | 2023 | β |
| Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors. | Γlvarez-Prado ΓF et al. | β | 2023 | β |
| Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors. | Sun C et al. | β | 2023 | β |
| Impact of Whole Genome Doubling on Detection of Circulating Tumor DNA in Colorectal Cancer. | Kabel J et al. | β | 2023 | β |
| Inferring early genetic progression in cancers with unobtainable premalignant disease. | Leshchiner I et al. | β | 2023 | β |
| Inflammation in the tumor-adjacent lung as a predictor of clinical outcome in lung adenocarcinoma. | Dolgalev I et al. | β | 2023 | β |
| Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer. | Cotto KC et al. | β | 2023 | β |
| Integrated analysis of racial disparities in genomic architecture identifies a trans-ancestry prognostic subtype in bladder cancer. | Zhang B et al. | β | 2023 | β |
| Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial. | Zang J et al. | β | 2023 | β |
| Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures. | Hu LS et al. | β | 2023 | β |
| Integrated molecular characterization of esophageal basaloid squamous cell carcinoma: a subtype with distinct RNA expression pattern and immune characteristics, but no specific genetic mutations. | Li Y et al. | β | 2023 | β |
| Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer. | Du M et al. | β | 2023 | β |
| Integrated Multi-Omics Landscape of Liver Metastases. | Yang S et al. | β | 2023 | β |
| Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin. | Liang WW et al. | β | 2023 | β |
| Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer. | Pradat Y et al. | β | 2023 | β |
| Integrative proteomic characterization of adenocarcinoma of esophagogastric junction. | Li S et al. | β | 2023 | β |
| Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma. | Yu Z et al. | β | 2023 | β |
| Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. | Perelli L et al. | β | 2023 | β |
| Intratumor heterogeneity in colorectal cancer: Distribution of tumor suppressor gene variants with regard to patient lymph node status. | WΔ tor G et al. | β | 2023 | β |
| Intratumor heterogeneity is associated with less CD8<sup>+</sup> T cell infiltration and worse survival in patients with small cell lung cancer. | Zhang C et al. | β | 2023 | β |
| Intra-tumor heterogeneity, turnover rate and karyotype space shape susceptibility to missegregation-induced extinction. | Kimmel GJ et al. | β | 2023 | β |
| Investigation of somatic mutation profiles and tumor evolution of primary oropharyngeal cancer and sequential lymph node metastases using multiregional whole-exome sequencing. | Sim NS et al. | β | 2023 | β |
| JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States. | Stevens LE et al. | β | 2023 | β |
| KIT A502_Y503 duplication mutation serves as a potential and universal target for neoantigen peptide in Chinese GIST patients. | Liu F et al. | β | 2023 | β |
| KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics. | Voutsadakis IA | β | 2023 | β |
| Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma. | Yang Z et al. | β | 2023 | β |
| Leading the pack: Best practices in comparative canine cancer genomics to inform human oncology. | London CA et al. | β | 2023 | β |
| Lineage Plasticity and Stemness Phenotypes in Prostate Cancer: Harnessing the Power of Integrated "Omics" Approaches to Explore Measurable Metrics. | Logotheti S et al. | β | 2023 | β |
| Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors. | Groves A et al. | β | 2023 | β |
| Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer. | Li X et al. | β | 2023 | β |
| Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction. | MΓΌller M et al. | β | 2023 | β |
| Malignant Histiocytosis Comprises a Phenotypic Spectrum That Parallels the Lineage Differentiation of Monocytes, Macrophages, Dendritic Cells, and Langerhans Cells. | Ravindran A et al. | β | 2023 | β |
| Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. | de Miguel FJ et al. | β | 2023 | β |
| Melanoma in a patient with DNMT3A overgrowth syndrome. | Chen DY et al. | β | 2023 | β |
| MEN1 Degradation Induced by Neddylation and the CUL4B-DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression. | Xu J et al. | β | 2023 | β |
| Metastatic insulinoma: exploration from clinicopathological signatures and genetic characteristics. | Zhang J et al. | β | 2023 | β |
| MHC II immunogenicity shapes the neoepitope landscape in human tumors. | Kim JY et al. | β | 2023 | β |
| MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology. | Dutta AK et al. | β | 2023 | β |
| Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. | Bomken S et al. | β | 2023 | β |
| Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer. | Wang Z et al. | β | 2023 | β |
| Molecular characterization of sub-frontal recurrent medulloblastomas reveals potential clinical relevance. | Chen Z et al. | β | 2023 | β |
| Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies. | Mondello P et al. | β | 2023 | β |
| Molecular evolution in different subtypes ofΒ multifocal hepatocellular carcinoma. | Tang X et al. | β | 2023 | β |
| Mosaic variants detectable in blood extend the clinicogenetic spectrum of <i>GLI3</i>-related hypothalamic hamartoma. | Green TE et al. | β | 2023 | β |
| Multicellular network analysis of melanoma heterogeneity by scRNA-seq. | Li S et al. | β | 2023 | β |
| Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma. | Kaya NA et al. | β | 2023 | β |
| Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature. | Li Q et al. | β | 2023 | β |
| Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Suppiah S et al. | β | 2023 | β |
| Mutational landscape of intestinal crypt cells after long-term in vivo exposure to high fat diet. | Meyenberg M et al. | β | 2023 | β |
| Mutational landscape of primary spinal cord astrocytoma. | Cheng L et al. | β | 2023 | β |
| Mutational pattern off homologous recombination repair (HRR)-related genes in upper tract urothelial carcinoma. | Yang K et al. | β | 2023 | β |
| Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma. | Wei C et al. | β | 2023 | β |
| Nasopharyngeal carcinoma patient-derived xenograft mouse models reveal potential drugs targeting cell cycle, mTOR, and autophagy pathways. | Li HP et al. | β | 2023 | β |
| Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma. | Patel R et al. | β | 2023 | β |
| Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. | Hall MS et al. | β | 2023 | β |
| Neoantigen-targeted CD8<sup>+</sup> T cell responses with PD-1 blockade therapy. | Puig-Saus C et al. | β | 2023 | β |
| Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy. | Borch A et al. | β | 2023 | β |
| Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. | Vos JL et al. | β | 2023 | β |
| Noninvasive genomic profiling of somatic mutations in oral cavity cancers. | Xi Y et al. | β | 2023 | β |
| Non-synonymous, synonymous, and non-coding nucleotide variants contribute to recurrently altered biological processes during retinoblastoma progression. | Stachelek K et al. | β | 2023 | β |
| Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study. | Zhou S et al. | β | 2023 | β |
| Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease. | Chen CH et al. | β | 2023 | β |
| NR4A3 Expression Is Consistently Absent in Acinic Cell Carcinomas of the Breast: A Potential Nosologic Shift. | Richardson ET et al. | β | 2023 | β |
| Optimized quantification of intra-host viral diversity in SARS-CoV-2 and influenza virus sequence data. | Roder AE et al. | β | 2023 | β |
| Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. | Geffen Y et al. | β | 2023 | β |
| Pan-cancer proteogenomics connects oncogenic drivers to functional states. | Li Y et al. | β | 2023 | β |
| Parallel sequencing of extrachromosomal circular DNAs and transcriptomes in single cancer cells. | Chamorro GonzΓ‘lez R et al. | β | 2023 | β |
| Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management. | McGee RB et al. | β | 2023 | β |
| PD-L1 expression-related PI3K pathway correlates with immunotherapy efficacy in gastric cancer. | Liu L et al. | β | 2023 | β |
| Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer. | Cheng L et al. | β | 2023 | β |
| Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. | Monge C et al. | β | 2023 | β |
| Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. | AndrΓ© F et al. | β | 2023 | β |
| Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model. | Wang J et al. | β | 2023 | β |
| Potential immunosuppressive clonal hematopoietic mutations in tumor infiltrating immune cells in breast invasive carcinoma. | Anandakrishnan R et al. | β | 2023 | β |
| Potential value of ctDNA monitoring in metastatic HRβ+β/HER2β-βbreast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial. | Chiu J et al. | β | 2023 | β |
| Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma. | Grommes C et al. | β | 2023 | β |
| Preclinical investigation of patient-derived cervical cancer organoids for precision medicine. | Seol HS et al. | β | 2023 | β |
| Prediction model of clinical prognosis and immunotherapy efficacy of gastric cancer based on level of expression of cuproptosis-related genes. | Zhao B et al. | β | 2023 | β |
| Predictive modelling for the diagnosis of oral and laryngeal premalignant and malignant lesions using p53 and Ki-67 expression. | Jeong JS et al. | β | 2023 | β |
| Preliminary evaluation of deep learning for first-line diagnostic prediction of tumor mutational status. | Morel LO et al. | β | 2023 | β |
| Profilin 1 deficiency drives mitotic defects and reduces genome stability. | Scotto di Carlo F et al. | β | 2023 | β |
| Prognostic and predictive impact of molecular tumor burden index in non-small cell lung cancer patients. | Yang F et al. | β | 2023 | β |
| Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer. | Zhang J et al. | β | 2023 | β |
| Proteogenomic insights suggest druggable pathways in endometrial carcinoma. | Dou Y et al. | β | 2023 | β |
| Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ. | Yao Z et al. | β | 2023 | β |
| Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. | Wang Y et al. | β | 2023 | β |
| PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. | Chen H et al. | β | 2023 | β |
| Quantification of rare somatic single nucleotide variants by droplet digital PCR using SuperSelective primers. | Pablo-Fontecha V et al. | β | 2023 | β |
| Rare variant associations with plasma protein levels in the UK Biobank. | Dhindsa RS et al. | β | 2023 | β |
| Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma. | Lee YP et al. | β | 2023 | β |
| Renal neuroendocrine tumors: clinical and molecular pathology with an emphasis on frequent association with ectopic Cushing syndrome. | Kasajima A et al. | β | 2023 | β |
| Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349βCβ>βG (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer. | Yang Z et al. | β | 2023 | β |
| satmut_utils: a simulation and variant calling package for multiplexed assays of variant effect. | Hoskins I et al. | β | 2023 | β |
| SETD8, a frequently mutated gene in cervical cancer, enhances cisplatin sensitivity by impairing DNA repair. | Wang X et al. | β | 2023 | β |
| Shining a light on the dark proteome: Non-canonical open reading frames and their encoded miniproteins as a new frontier in cancer biology. | Posner Z et al. | β | 2023 | β |
| Simple combination of multiple somatic variant callers to increase accuracy. | Trevarton AJ et al. | β | 2023 | β |
| Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma. | Yao L et al. | β | 2023 | β |
| Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET. | Zhang Q et al. | β | 2023 | β |
| Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. | Zhang S et al. | β | 2023 | β |
| Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule. | Bruzos AL et al. | β | 2023 | β |
| Somatic mosaicism in inborn errors of immunity: Current knowledge, challenges, and future perspectives. | Aluri J et al. | β | 2023 | β |
| Somatic variant detection from multi-sampled genomic sequencing data of tumor specimens using the ith.Variant pipeline. | Maeser N et al. | β | 2023 | β |
| Spatial and clonality-resolved 3D cancer genome alterations reveal enhancer-hijacking as a potential prognostic marker for colorectal cancer. | Kim K et al. | β | 2023 | β |
| Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression. | Huang KK et al. | β | 2023 | β |
| Specific genetic aberrations of parathyroid in Chinese patients with tertiary hyperparathyroidism using whole-exome sequencing. | Li L et al. | β | 2023 | β |
| SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation. | Chen CW et al. | β | 2023 | β |
| Striated muscle-specific base editing enables correction of mutations causing dilated cardiomyopathy. | Grosch M et al. | β | 2023 | β |
| Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma. | Kinnaman MD et al. | β | 2023 | β |
| Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy. | Vornholz L et al. | β | 2023 | β |
| T cell receptor and B cell receptor exhibit unique signatures in tumor and adjacent non-tumor tissues of hepatocellular carcinoma. | Xie S et al. | β | 2023 | β |
| Technological and computational approaches to detect somatic mosaicism in epilepsy. | BoΓelmann CM et al. | β | 2023 | β |
| Test development, optimization and validation of a WGS pipeline for genetic disorders. | Yang Z et al. | β | 2023 | β |
| The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization. | Bronkhorst AJ et al. | β | 2023 | β |
| The effects of altered DNA damage repair genes on mutational processes and immune cell infiltration in esophageal squamous cell carcinoma. | Yuan H et al. | β | 2023 | β |
| The epigenetic modifier lysine methyltransferase 2C is frequently mutated in gastric remnant carcinoma. | Sun B et al. | β | 2023 | β |
| The evolution of lung cancer and impact of subclonal selection in TRACERx. | Frankell AM et al. | β | 2023 | β |
| The genetic determinants of recurrent somatic mutations in 43,693 blood genomes. | Weinstock JS et al. | β | 2023 | β |
| The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. | Lundberg A et al. | β | 2023 | β |
| The genomic landscape across 474 surgically accessible epileptogenic human brain lesions. | LΓ³pez-Rivera JA et al. | β | 2023 | β |
| The impact of the Hedgehog signal pathway on the tumor immune microenvironment of gastric adenocarcinoma by integrated analysis of scRNA-seq and RNA-seq datasets. | Zhong J et al. | β | 2023 | β |
| The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity. | Wang Y et al. | β | 2023 | β |
| The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers. | Vellichirammal NN et al. | β | 2023 | β |
| The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response. | Chen J et al. | β | 2023 | β |
| The origins and functional effects of postzygotic mutations throughout the human life span. | Rockweiler NB et al. | β | 2023 | β |
| Therapy-induced APOBEC3A drives evolution of persistent cancer cells. | Isozaki H et al. | β | 2023 | β |
| Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade. | Nazerai L et al. | β | 2023 | β |
| Toward Precision Oncology in Glioblastoma with a Personalized Cancer Genome Reporting Tool and Genetic Changes Identified by Whole Exome Sequencing. | Erdogan O et al. | β | 2023 | β |
| Tracking the evolution of esophageal squamous cell carcinoma under dynamic immune selection by multi-omics sequencing. | Cui S et al. | β | 2023 | β |
| Transcriptome-based identification of tumor-reactive and bystander CD8<sup>+</sup> T cell receptor clonotypes in human pancreatic cancer. | Meng Z et al. | β | 2023 | β |
| Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia. | Kim JC et al. | β | 2023 | β |
| Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. | Mosele F et al. | β | 2023 | β |
| TSC2 inactivation, low mutation burden and high macrophage infiltration characterise hepatic angiomyolipomas. | Giannikou K et al. | β | 2023 | β |
| Tumor grade-associated genomic mutations in Chinese patients with non-small cell lung cancer. | Wang Y et al. | β | 2023 | β |
| Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma. | Hu J et al. | β | 2023 | β |
| Tumor-NaΓ―ve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials. | Sanz-Garcia E et al. | β | 2023 | β |
| Tutorial: integrative computational analysis of bulk RNA-sequencing data to characterize tumor immunity using RIMA. | Yang L et al. | β | 2023 | β |
| Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. | Griffin GK et al. | β | 2023 | β |
| Utilizing immunogenomic approaches to prioritize targetable neoantigens for personalized cancer immunotherapy. | Shah RK et al. | β | 2023 | β |
| Validation and benchmarking of targeted panel sequencing for cancer genomic profiling. | Wang D et al. | β | 2023 | β |
| Validation of genetic variants from NGS data using deep convolutional neural networks. | Vaisband M et al. | β | 2023 | β |
| Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome. | Thomson JP et al. | β | 2023 | β |
| Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA. | Zhou C et al. | β | 2023 | β |
| Whole genome sequencing in high-grade cervical intraepithelial neoplasia patients from different ethnic groups in China. | Wang J et al. | β | 2023 | β |
| Whole-genome sequencing of 20 cholangiocarcinoma cases reveals unique profiles in patients with cirrhosis and primary sclerosing cholangitis. | Holzapfel N et al. | β | 2023 | β |
| Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues. | Abelin JG et al. | β | 2023 | β |
| A prognostic risk model for glioma patients by systematic evaluation of genomic variations. | Zhang B et al. | β | 2022 | β |
| Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer. | Tsuji J et al. | β | 2022 | β |
| Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer. | Silveira C et al. | β | 2022 | β |
| Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention. | Giraldo NA et al. | β | 2022 | β |
| CT Radiomics and Whole Genome Sequencing in Patients with Pancreatic Ductal Adenocarcinoma: Predictive Radiogenomics Modeling. | Hinzpeter R et al. | β | 2022 | β |
| DeteX: A highly accurate software for detecting SNV and InDel in single and paired NGS data in cancer research. | Cui Y et al. | β | 2022 | β |
| Frequent somatic mosaicism in T lymphocyte subsets in individuals with and without multiple sclerosis. | Van Horebeek L et al. | β | 2022 | β |
| Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. | Wong KK et al. | β | 2022 | β |
| Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer. | Perez-Villatoro F et al. | β | 2022 | β |
| Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer. | Xue C et al. | β | 2022 | β |
| Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma. | Tong Y et al. | β | 2022 | β |
| Somatic Variants in SVIL in Cerebral Aneurysms. | Lai PMR et al. | β | 2022 | β |
| Spatial heterogeneity of infiltrating TΒ cells in high-grade serous ovarian cancer revealed by multi-omics analysis. | Yang B et al. | β | 2022 | β |
| Stress combined with loss of the Candida albicans SUMO protease Ulp2 triggers selection of aneuploidy via a two-step process. | Rizzo M et al. | β | 2022 | β |
| TLsub: A transfer learning based enhancement to accurately detect mutations with wide-spectrum sub-clonal proportion. | Zheng T | β | 2022 | β |
| TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with <i>TP53</i> Mutation/Deletion. | Eisenmann ED et al. | β | 2022 | β |
| Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma. | Wang J et al. | β | 2022 | β |
| Whole exome sequencing in Chinese mucinous pulmonary adenocarcinoma uncovers specific genetic variations different from lung adenocarcinoma. | Zhang C et al. | β | 2022 | β |
| Whole genome sequencing of Malaysian colorectal cancer patients reveals specific druggable somatic mutations. | Mohd Yunos RI et al. | β | 2022 | β |
| XCVATR: detection and characterization of variant impact on the Embeddings of single -cell and bulk RNA-sequencing samples. | Harmanci A et al. | β | 2022 | β |